

Peter J Barnes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4848033/publications.pdf>

Version: 2024-02-01

914
papers

114,027
citations

168

157
h-index

272

305
g-index

956
all docs

956
docs citations

956
times ranked

64132
citing authors

#	ARTICLE	IF	CITATIONS
1	Accelerated Lung Aging and Cellular Senescence in COPD. , 2022, , 583-593.		0
2	Other Drugs for Asthma and COPD. , 2022, , 729-740.		0
3	Inflammatory and Immune Mechanisms in COPD. , 2022, , 549-558.		0
4	Pulmonary infection by SARS-CoV-2 induces senescence accompanied by an inflammatory phenotype in severe COVID-19: possible implications for viral mutagenesis. European Respiratory Journal, 2022, 60, 2102951.	3.1	56
5	Inhaled corticosteroids reduce senescence in endothelial progenitor cells from patients with COPD. Thorax, 2022, 77, 616-620.	2.7	8
6	Blood Eosinophils in Chinese COPD Participants and Response to Treatment with Combination Low-Dose Theophylline and Prednisone: A Post-Hoc Analysis of the TASCs Trial. International Journal of COPD, 2022, Volume 17, 273-282.	0.9	0
7	Is inhaler technique adequately assessed and reported in clinical trials of asthma and COPD therapy? A systematic review and suggested best practice checklist.. Journal of Allergy and Clinical Immunology: in Practice, 2022, , .	2.0	5
8	Chemokine receptor CCR1: new target for asthma therapy. Trends in Pharmacological Sciences, 2022, , .	4.0	0
9	Identification of coronavirus particles by electron microscopy: a complementary tool for deciphering COVID-19. European Respiratory Journal, 2022, , 2200754.	3.1	1
10	Oxidative Stress in Chronic Obstructive Pulmonary Disease. Antioxidants, 2022, 11, 965.	2.2	54
11	Autophagy in asthma and chronic obstructive pulmonary disease. Clinical Science, 2022, 136, 733-746.	1.8	20
12	IL-36 receptor agonist and antagonist imbalance drives neutrophilic inflammation in COPD. JCI Insight, 2022, 7, .	2.3	8
13	Endo-phenotyping of COPD patients. Expert Review of Respiratory Medicine, 2021, 15, 27-37.	1.0	20
14	Effect of a single day of increased as-needed budesonide+formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study. Lancet Respiratory Medicine,the, 2021, 9, 149-158.	5.2	46
15	Targeting cellular senescence as a new approach to chronic obstructive pulmonary disease therapy. Current Opinion in Pharmacology, 2021, 56, 68-73.	1.7	13
16	The effect of low-dose corticosteroids and theophylline on the risk of acute exacerbations of COPD: the TASCs randomised controlled trial. European Respiratory Journal, 2021, 57, 2003338.	3.1	24
17	Cigarette smoke-induced impairment of autophagy in macrophages increases galectin-8 and inflammation. Scientific Reports, 2021, 11, 335.	1.6	18
18	Chronic lung diseases: prospects for regeneration and repair. European Respiratory Review, 2021, 30, 200213.	3.0	16

#	ARTICLE	IF	CITATIONS
19	Low BMI and weight loss aggravate COPD mortality in men, findings from a large prospective cohort: the JACC study. <i>Scientific Reports</i> , 2021, 11, 1531.	1.6	26
20	Safety of As-Needed Budesonide-Formoterol in Mild Asthma: Data from the Two Phase III SYGMA Studies. <i>Drug Safety</i> , 2021, 44, 467-478.	1.4	8
21	Effectiveness of low-dose theophylline for the management of biomass-associated COPD (LODOT-BCOPD): study protocol for a randomized controlled trial. <i>Trials</i> , 2021, 22, 213.	0.7	4
22	Positioning As-needed Budesonide-Formoterol for Mild Asthma: Effect of Prestudy Treatment in Pooled Analysis of SYGMA 1 and 2. <i>Annals of the American Thoracic Society</i> , 2021, 18, 2007-2017.	1.5	17
23	Case Report: Ketogenic Diet Is Associated With Improvements in Chronic Obstructive Pulmonary Disease. <i>Frontiers in Medicine</i> , 2021, 8, 699427.	1.2	3
24	Efficacy and Safety of As-Needed Budesonide-Formoterol in Adolescents with Mild Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3069-3077.e6.	2.0	22
25	Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. <i>Lancet, The</i> , 2021, 398, 843-855.	6.3	204
26	Asthmatic patients. , 2021, , 136-153.		0
27	Reply to "As-needed budesonide-formoterol for adolescents with mild asthma: importance of lung function" <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 4179-4180.	2.0	0
28	Extracellular vesicles produced by airway epithelial cells in response to oxidative stress contain microRNAs associated with cellular senescence. , 2021, , .		0
29	IL-36? " a key mediator of neutrophilic inflammation in chronic obstructive pulmonary disease. , 2021, , .		0
30	Mitochondrial dysfunction in lung ageing and disease. <i>European Respiratory Review</i> , 2020, 29, 200165.	3.0	56
31	The Hidden Burden of Severe Asthma: From Patient Perspective to New Opportunities for Clinicians. <i>Journal of Clinical Medicine</i> , 2020, 9, 2397.	1.0	6
32	The burden of exacerbations in mild asthma: a systematic review. <i>ERJ Open Research</i> , 2020, 6, 00359-2019.	1.1	33
33	Hepcidin Is Essential for Alveolar Macrophage Function and Is Disrupted by Smoke in a Murine Chronic Obstructive Pulmonary Disease Model. <i>Journal of Immunology</i> , 2020, 205, 2489-2498.	0.4	13
34	Sex and gender: modifiers of health, disease, and medicine. <i>Lancet, The</i> , 2020, 396, 565-582.	6.3	955
35	Virus-Induced Asthma Exacerbations: SIRT1 Targeted Approach. <i>Journal of Clinical Medicine</i> , 2020, 9, 2623.	1.0	8
36	COPD 2020: new directions needed. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2020, 319, L884-L886.	1.3	32

#	ARTICLE	IF	CITATIONS
37	Chronic Obstructive Pulmonary Disease Endotypes in Low- and Middle-Income Country Settings: Precision Medicine for All. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 171-172.	2.5	17
38	The evolving algorithm of biological selection in severe asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1555-1563.	2.7	30
39	Phenotypic comparison between smoking and non-smoking chronic obstructive pulmonary disease. Respiratory Research, 2020, 21, 50.	1.4	57
40	Senotherapy. Chest, 2020, 158, 562-570.	0.4	44
41	No Evidence That Electric Charge Increases Inhaled Ultrafine Particle Deposition in Human Lungs. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1301-1303.	2.5	4
42	Oxidative stress-based therapeutics in COPD. Redox Biology, 2020, 33, 101544.	3.9	210
43	Towards easier, faster, super-resolved microscopy. , 2020, , .		0
44	Altered iron metabolism and elevated cellular senescence in COPD small airway epithelial cells. , 2020, , .		0
45	Analysis of defective phagocytosis in COPD using super-resolution microscopy and automated bacterial quantification. , 2020, , .		0
46	Efficacy of as-needed budesonide/formoterol in mild asthma: pooled analysis of SYGMA 1 and 2. , 2020, , .		0
47	LSC - 2020 - Extracellular vesicles produced by bronchial epithelial cells in response to oxidative stress contain micro-RNAs associated with senescence. , 2020, , .		0
48	Nitrosative stress in patients with asthma~chronic obstructive pulmonary disease overlap. Journal of Allergy and Clinical Immunology, 2019, 144, 928-930.	1.5	4
49	Defective bacterial phagocytosis is associated with dysfunctional mitochondria in COPD macrophages. European Respiratory Journal, 2019, 54, 1802244.	3.1	86
50	Small airway fibrosis in COPD. International Journal of Biochemistry and Cell Biology, 2019, 116, 105598.	1.2	60
51	Symptoms and perception of airway obstruction in asthmatic patients: Clinical implications for use of reliever medications. Journal of Allergy and Clinical Immunology, 2019, 144, 1180-1186.	1.5	45
52	Dual mechanism of action of T2 inhibitor therapies in virally induced exacerbations of asthma: evidence for a beneficial counter-regulation. European Respiratory Journal, 2019, 54, 1802390.	3.1	12
53	Pulmonary Diseases and Ageing. Sub-Cellular Biochemistry, 2019, 91, 45-74.	1.0	29
54	Inflammatory endotypes in COPD. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1249-1256.	2.7	147

#	ARTICLE	IF	CITATIONS
55	Cellular Senescence as a Mechanism and Target in Chronic Lung Diseases. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 556-564.	2.5	282
56	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. European Respiratory Journal, 2019, 53, 1900164.	3.1	1,223
57	Dynein Has Defective Activity in COPD Macrophage Phagocytosis. , 2019, , .		0
58	Bicaudal D1 impairs autophagosome maturation in chronic obstructive pulmonary disease. FASEB BioAdvances, 2019, 1, 688-705.	1.3	14
59	MicroRNA-570 is a novel regulator of cellular senescence and inflammaging. FASEB Journal, 2019, 33, 1605-1616.	0.2	64
60	Can We Define Asthma-COPD Overlap (ACO) by Biomarkers?. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 146-147.	2.0	10
61	Direct Inhibitory Effect of the PDE4 Inhibitor Roflumilast on Neutrophil Migration in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory Cell and Molecular Biology, 2019, 60, 445-453.	1.4	35
62	Bacterial load and defective monocyte-derived macrophage bacterial phagocytosis in biomass smoke-related COPD. European Respiratory Journal, 2019, 53, 1702273.	3.1	30
63	Ezrin, a Membrane Cytoskeleton Cross-Linker Protein, as a Marker of Epithelial Damage in Asthma. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 496-507.	2.5	35
64	Automated multiwell plate STORM: towards open source super-resolved high content analysis. , 2019, , .		1
65	Exacerbation risk after night-time waking due to asthma in SYGMA 1. , 2019, , .		1
66	Number needed to treat (NNT) to have an additional patient free from a severe or moderate/severe exacerbation: post-hoc analysis of SYGMA 1 in mild asthma. , 2019, , .		1
67	Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT. Health Technology Assessment, 2019, 23, 1-146.	1.3	7
68	Pharmacology of asthma and COPD. , 2019, , 344-352.		0
69	The Pressing Need to Redefine "COPD". Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2019, 6, 380-383.	0.5	12
70	Differential phosphorylation patterns of macrophage cytoskeletal proteins in COPD following phagocytosis. , 2019, , .		0
71	Pharmacological treatment of COPD: the devil is always in the detail. European Respiratory Journal, 2018, 51, 1800263.	3.1	16
72	Targeting cytokines to treat asthma and chronic obstructive pulmonary disease. Nature Reviews Immunology, 2018, 18, 454-466.	10.6	272

#	ARTICLE	IF	CITATIONS
73	TGF- β 2 Signaling Pathways in Different Compartments of the Lower Airways of Patients With Stable COPD. <i>Chest</i> , 2018, 153, 851-862.	0.4	43
74	ERS/ATS workshop report on respiratory health effects of household air pollution. <i>European Respiratory Journal</i> , 2018, 51, 1700698.	3.1	81
75	Efficacy and safety profile of xanthines in COPD: a network meta-analysis. <i>European Respiratory Review</i> , 2018, 27, 180010.	3.0	41
76	Downregulation of MicroRNA-126 Augments DNA Damage Response in Cigarette Smokers and Patients with Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 665-668.	2.5	36
77	Mitochondria, telomeres and cell senescence: Implications for lung ageing and disease. , 2018, 183, 34-49.		128
78	Budesonide facilitates weaning from mechanical ventilation in difficult-to-wean very severe COPD patients: Association with inflammatory mediators and cells. <i>Journal of Critical Care</i> , 2018, 44, 161-167.	1.0	10
79	5 α -...Therapy for asthma and COPD. , 2018, , .		0
80	Effect of Theophylline as Adjunct to Inhaled Corticosteroids on Exacerbations in Patients With COPD. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1548.	3.8	67
81	Looking for Airways Perilastin in Severe Asthma. <i>Chest</i> , 2018, 154, 1083-1090.	0.4	25
82	Inhaled Combined Budesonide β 2-Formoterol as Needed in Mild Asthma. <i>New England Journal of Medicine</i> , 2018, 378, 1865-1876.	13.9	453
83	As-Needed Budesonide β 2-Formoterol versus Maintenance Budesonide in Mild Asthma. <i>New England Journal of Medicine</i> , 2018, 378, 1877-1887.	13.9	368
84	Breathomics for Assessing the Effects of Treatment and Withdrawal With Inhaled Beclomethasone/Formoterol in Patients With COPD. <i>Frontiers in Pharmacology</i> , 2018, 9, 258.	1.6	25
85	Pre-clinical Pharmacokinetic and Metabolomic Analyses of Isorhapontigenin, a Dietary Resveratrol Derivative. <i>Frontiers in Pharmacology</i> , 2018, 9, 753.	1.6	28
86	Late Breaking Abstract - Risk of a severe exacerbation following higher reliever use: post-hoc analysis of SYGMA 1 in mild asthma. , 2018, , .		1
87	Recent Advances in Asthma Management. <i>European Respiratory & Pulmonary Diseases</i> , 2018, 4, 15.	0.2	0
88	Efficacy and safety profile of xanthines in COPD: a network meta-analysis. , 2018, , .		1
89	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 557-582.	2.5	2,393
90	Impaired Dual-Specificity Protein Phosphatase DUSP4 Reduces Corticosteroid Sensitivity. <i>Molecular Pharmacology</i> , 2017, 91, 475-481.	1.0	11

#	ARTICLE	IF	CITATIONS
91	GOLD 2017. <i>Chest</i> , 2017, 151, 245-246.	0.4	11
92	Painful subcutaneous nodules in a patch of livedo reticularis. <i>International Journal of Dermatology</i> , 2017, 56, e44-e46.	0.5	3
93	A European Respiratory Society technical standard: exhaled biomarkers in lung disease. <i>European Respiratory Journal</i> , 2017, 49, 1600965.	3.1	432
94	Decreased Serum Sirtuin-1 in COPD. <i>Chest</i> , 2017, 152, 343-352.	0.4	51
95	Decreased phosphatase PTEN amplifies PI3K signaling and enhances proinflammatory cytokine release in COPD. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2017, 313, L230-L239.	1.3	47
96	Bronchial inflammation and bacterial load in stable COPD is associated with TLR4 overexpression. <i>European Respiratory Journal</i> , 2017, 49, 1602006.	3.1	63
97	Impaired Mitochondrial Microbicidal Responses in Chronic Obstructive Pulmonary Disease Macrophages. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 845-855.	2.5	70
98	Increased neutrophil gelatinase-associated lipocalin (NGAL) promotes airway remodelling in chronic obstructive pulmonary disease. <i>Clinical Science</i> , 2017, 131, 1147-1159.	1.8	52
99	Isorhapontigenin, a bioavailable dietary polyphenol, suppresses airway epithelial cell inflammation through a corticosteroid-independent mechanism. <i>British Journal of Pharmacology</i> , 2017, 174, 2043-2059.	2.7	56
100	A Randomized Pragmatic Trial of Changing to and Stepping Down Fluticasone/Formoterol in Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 1378-1387.e5.	2.0	27
101	Validation of the Exhaled Breath Temperature Measure. <i>Chest</i> , 2017, 151, 855-860.	0.4	23
102	New Therapies for Asthma and Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 159-166.	2.5	87
103	Professor Neil B. ÅPride (1931-2016). <i>European Respiratory Journal</i> , 2017, 49, 1602343.	3.1	0
104	Senescence in COPD and Its Comorbidities. <i>Annual Review of Physiology</i> , 2017, 79, 517-539.	5.6	190
105	Effects of an Airway Clearance Device on Inflammation, Bacteriology, and Mucus Transport in Bronchiectasis. <i>Respiratory Care</i> , 2017, 62, 1067-1074.	0.8	13
106	Quercetin restores corticosteroid sensitivity in cells from patients with chronic obstructive pulmonary disease. <i>Experimental Lung Research</i> , 2017, 43, 417-425.	0.5	30
107	Reduced HDAC2 in skeletal muscle of COPD patients. <i>Respiratory Research</i> , 2017, 18, 99.	1.4	22
108	Cellular and molecular mechanisms of asthma and COPD. <i>Clinical Science</i> , 2017, 131, 1541-1558.	1.8	339

#	ARTICLE	IF	CITATIONS
109	COUNTERPOINT: Will New Anti-eosinophilic Drugs Be Useful in Asthma Management? No. Chest, 2017, 151, 17-20.	0.4	11
110	Rebuttal From Dr Barnes. Chest, 2017, 151, 21-22.	0.4	0
111	Dilemmas, Confusion, and Misconceptions Related to Small Airways Directed Therapy. Chest, 2017, 151, 1345-1355.	0.4	49
112	Inflammatory Mechanisms in Chronic Obstructive Pulmonary Disease. , 2017, , 1173-1198.		1
113	P53...Phosphoinositide-3 kinase and mek inhibition prevents uptake of bacteria by airway epithelial cells. , 2017, , .		0
114	Kinases as Novel Therapeutic Targets in Asthma and Chronic Obstructive Pulmonary Disease. Pharmacological Reviews, 2016, 68, 788-815.	7.1	93
115	Simvastatin up-regulates adenosine deaminase and suppresses osteopontin expression in COPD patients through an IL-13-dependent mechanism. Respiratory Research, 2016, 17, 104.	1.4	23
116	Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology, 2016, 138, 16-27.	1.5	956
117	Corticosteroid modulation of immunoglobulin expression and B cell function in COPD. FASEB Journal, 2016, 30, 2014-2026.	0.2	29
118	Asthma mechanisms. Medicine, 2016, 44, 265-270.	0.2	14
119	Sex Differences in Chronic Obstructive Pulmonary Disease Mechanisms. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 813-814.	2.5	104
120	Oral Low-dose Theophylline on Top of Inhaled Fluticasone-Salmeterol Does Not Reduce Exacerbations in Patients With Severe COPD. Chest, 2016, 150, 123-130.	0.4	50
121	The prevalence of small airways disease in adult asthma: A systematic literature review. Respiratory Medicine, 2016, 116, 19-27.	1.3	99
122	Repeated lipopolysaccharide exposure causes corticosteroid insensitive airway inflammation via activation of phosphoinositide-3-kinase γ pathway. Biochemistry and Biophysics Reports, 2016, 7, 367-373.	0.7	13
123	Extracellular Adenosine 5'-Triphosphate in Obstructive Airway Diseases. Chest, 2016, 150, 908-915.	0.4	37
124	Pathogenesis of COPD and Asthma. Handbook of Experimental Pharmacology, 2016, 237, 1-21.	0.9	23
125	Glucocorticosteroids. Handbook of Experimental Pharmacology, 2016, 237, 93-115.	0.9	110
126	Inhaled Aerosol Distribution in Human Airways: A Scintigraphy-Guided Study in a 3D Printed Model. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2016, 29, 525-533.	0.7	27

#	ARTICLE	IF	CITATIONS
127	Protein tyrosine phosphatase PTP-RR regulates corticosteroid sensitivity. <i>Respiratory Research</i> , 2016, 17, 30.	1.4	10
128	Defective sirtuin-1 increases IL-4 expression through acetylation of GATA-3 in patients with severe asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 1595-1597.e7.	1.5	36
129	Oxidative and Nitrosative Stress and Histone Deacetylase-2 Activity in Exacerbations of COPD. <i>Chest</i> , 2016, 149, 62-73.	0.4	70
130	Giants in Chest Medicine. <i>Chest</i> , 2016, 149, 619-620.	0.4	0
131	Enhanced monocyte migration to CXCR3 and CCR5 chemokines in COPD. <i>European Respiratory Journal</i> , 2016, 47, 1093-1102.	3.1	53
132	Asthma-COPD Overlap. <i>Chest</i> , 2016, 149, 7-8.	0.4	86
133	The effect of body weight on distal airway function and airway inflammation. <i>Obesity Research and Clinical Practice</i> , 2016, 10, 564-573.	0.8	20
134	Restoration of Corticosteroid Sensitivity in Chronic Obstructive Pulmonary Disease by Inhibition of Mammalian Target of Rapamycin. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 193, 143-153.	2.5	86
135	Differential Effects of p38, MAPK, PI3K or Rho Kinase Inhibitors on Bacterial Phagocytosis and Efferocytosis by Macrophages in COPD. <i>PLoS ONE</i> , 2016, 11, e0163139.	1.1	49
136	Evaluation of Individuals at Risk for COPD: Beyond the Scope of GOLD. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2016, 3, 653-667.	0.5	12
137	Simvastatin Suppresses Airway IL-17 and Upregulates IL-10 in Patients With Stable COPD. <i>Chest</i> , 2015, 148, 1164-1176.	0.4	53
138	Oscillating Positive Expiratory Pressure on Respiratory Resistance in Chronic Obstructive Pulmonary Disease With a Small Amount of Secretion. <i>Medicine (United States)</i> , 2015, 94, e1845.	0.4	16
139	Club Cells, Their Secretory Protein, and COPD. <i>Chest</i> , 2015, 147, 1447-1448.	0.4	23
140	Chronic obstructive pulmonary disease. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15076.	18.1	444
141	Klotho expression is reduced in COPD airway epithelial cells: effects on inflammation and oxidant injury. <i>Clinical Science</i> , 2015, 129, 1011-1023.	1.8	79
142	Glycogen synthase kinase-3 β modulation of glucocorticoid responsiveness in COPD. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2015, 309, L1112-L1123.	1.3	21
143	Bronchoabsorption; a novel bronchoscopic technique to improve biomarker sampling of the airway. <i>Respiratory Research</i> , 2015, 16, 102.	1.4	16
144	Use of low-dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial. <i>Trials</i> , 2015, 16, 267.	0.7	20

#	ARTICLE	IF	CITATIONS
145	Effect of JAK Inhibitors on Release of CXCL9, CXCL10 and CXCL11 from Human Airway Epithelial Cells. PLoS ONE, 2015, 10, e0128757.	1.1	44
146	An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. European Respiratory Review, 2015, 24, 159-172.	3.0	72
147	Microarray analysis of long non-coding RNAs in COPD lung tissue. Inflammation Research, 2015, 64, 119-126.	1.6	62
148	Mechanisms of development of multimorbidity in the elderly. European Respiratory Journal, 2015, 45, 790-806.	3.1	150
149	Glottal Aperture and Buccal Airflow Leaks Critically Affect Forced Oscillometry Measurements. Chest, 2015, 148, 731-738.	0.4	17
150	Updates in Chronic Obstructive Pulmonary Disease for the Year 2014. Turkish Thoracic Journal, 2015, 16, 86-96.	0.1	1
151	Oxidative stress-induced mitochondrial dysfunction drives inflammation and airway smooth muscle remodeling in patients with chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology, 2015, 136, 769-780.	1.5	332
152	Efficacy and safety of nebulized glycopyrrolate for administration using a high efficiency nebulizer in patients with chronic obstructive pulmonary disease. British Journal of Clinical Pharmacology, 2015, 79, 492-500.	1.1	26
153	Accelerated ageing of the lung in COPD: new concepts. Thorax, 2015, 70, 482-489.	2.7	250
154	An Official American Thoracic Society/European Respiratory Society Statement: Research Questions in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2015, 191, e4-e27.	2.5	166
155	An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. European Respiratory Journal, 2015, 45, 879-905.	3.1	138
156	Bronchial epithelial cells: The key effector cells in the pathogenesis of chronic obstructive pulmonary disease?. Respirology, 2015, 20, 722-729.	1.3	164
157	Identifying Molecular Targets for New Drug Development for Chronic Obstructive Pulmonary Disease: What Does the Future Hold?. Seminars in Respiratory and Critical Care Medicine, 2015, 36, 508-522.	0.8	28
158	The novel inhaled glucocorticoid receptor agonist GW870086X protects against adenosine-induced bronchoconstriction in asthma. Journal of Allergy and Clinical Immunology, 2015, 136, 501-502.e6.	1.5	9
159	Therapeutic approaches to asthma-chronic obstructive pulmonary disease overlap syndromes. Journal of Allergy and Clinical Immunology, 2015, 136, 531-545.	1.5	147
160	Interaction of Pattern Recognition Receptors with Mycobacterium Tuberculosis. Journal of Clinical Immunology, 2015, 35, 1-10.	2.0	129
161	Anti-inflammatory effects of resveratrol analogues in cellular models of airway inflammation. , 2015, , .		0
162	LSC Abstract - Rhinovirus infection induces NRF2 in monocytes but not in epithelial cells, via distinct intracellular pathways. , 2015, , .		0

#	ARTICLE	IF	CITATIONS
163	Brd4 Is Essential for IL-1 β -Induced Inflammation in Human Airway Epithelial Cells. PLoS ONE, 2014, 9, e95051.	1.1	90
164	Inflammatory thresholds and the species-specific effects of colonising bacteria in stable chronic obstructive pulmonary disease. Respiratory Research, 2014, 15, 114.	1.4	62
165	The effect of the novel phosphodiesterase-4 inhibitor MEM 1414 on the allergen induced responses in mild asthma. BMC Pulmonary Medicine, 2014, 14, 166.	0.8	17
166	A comprehensive analysis of oxidative stress in the ozone-induced lung inflammation mouse model. Clinical Science, 2014, 126, 425-440.	1.8	63
167	Passive Smoking Impairs Histone Deacetylase-2 in Children With Severe Asthma. Chest, 2014, 145, 305-312.	0.4	89
168	Glucocorticoids. Chemical Immunology and Allergy, 2014, 100, 311-316.	1.7	57
169	Decreased percentage of CD4+Foxp3+TGF- β 2+ and increased percentage of CD4+IL-17+ cells in bronchoalveolar lavage of asthmatics. Journal of Inflammation, 2014, 11, 22.	1.5	14
170	The European Respiratory Society plans its future: the 2013-2018 strategic plan. European Respiratory Journal, 2014, 43, 927-932.	3.1	15
171	What Does the Future Hold for the Therapy of COPD?. Milestones in Drug Therapy, 2014, , 129-146.	0.1	1
172	Identification of a distinct glucocorticosteroid-insensitive pulmonary macrophage phenotype in patients with chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology, 2014, 133, 207-216.e11.	1.5	51
173	Cellular and Molecular Mechanisms of Chronic Obstructive Pulmonary Disease. Clinics in Chest Medicine, 2014, 35, 71-86.	0.8	352
174	Sarcoidosis: Role of non-tuberculosis mycobacteria and Mycobacterium tuberculosis. International Journal of Mycobacteriology, 2014, 3, 225-229.	0.3	31
175	Impaired macrophage phagocytosis of bacteria in severe asthma. Respiratory Research, 2014, 15, 72.	1.4	85
176	Innate immunity but not NLRP3 inflammasome activation correlates with severity of stable COPD. Thorax, 2014, 69, 516-524.	2.7	99
177	Sputum myeloperoxidase in chronic obstructive pulmonary disease. European Journal of Medical Research, 2014, 19, 12.	0.9	47
178	Impact of theophylline/corticosteroid combination therapy on sputum hydrogen sulfide levels in patients with COPD. European Respiratory Journal, 2014, 43, 1504-1506.	3.1	19
179	Bromodomain and Extraterminal Proteins Suppress NF-E2-Related Factor 2-Mediated Antioxidant Gene Expression. Journal of Immunology, 2014, 192, 4913-4920.	0.4	61
180	Chronic Obstructive Pulmonary Disease. Clinics in Chest Medicine, 2014, 35, xiii.	0.8	5

#	ARTICLE	IF	CITATIONS
181	A Novel Approach to Partition Central and Peripheral Airway Nitric Oxide. <i>Chest</i> , 2014, 145, 113-119.	0.4	37
182	Hepatocyte Growth Factor Deficiency in COPD. <i>Chest</i> , 2014, 146, 1135-1136.	0.4	11
183	Giants in Chest Medicine. <i>Chest</i> , 2014, 146, 545-546.	0.4	0
184	Smoking Cessation in COPD Causes a Transient Improvement in Spirometry and Decreases Micronodules on High-Resolution CT Imaging. <i>Chest</i> , 2014, 145, 1006-1015.	0.4	18
185	Oxidative Stress in COPD. <i>Oxidative Stress in Applied Basic Research and Clinical Practice</i> , 2014, , 115-129.	0.4	1
186	Activation of Transcription Factor Nrf2 Signalling by the Sphingosine Kinase Inhibitor SKI-II Is Mediated by the Formation of Keap1 Dimers. <i>PLoS ONE</i> , 2014, 9, e88168.	1.1	21
187	Tumour Necrosis Factor- α Regulates Human Eosinophil Apoptosis via Ligation of TNF-Receptor 1 and Balance between NF- κ B and AP-1. <i>PLoS ONE</i> , 2014, 9, e90298.	1.1	47
188	Pathophysiology of Allergic Inflammation. , 2014, , 327-342.		1
189	Oxidative Stress in Chronic Obstructive Pulmonary Disease. , 2014, , 314-348.		2
190	Standardised exhaled breath collection for the measurement of exhaled volatile organic compounds by proton transfer reaction mass spectrometry. <i>BMC Pulmonary Medicine</i> , 2013, 13, 43.	0.8	61
191	Inhaled long-acting β 2 agonists enhance glucocorticoid receptor nuclear translocation and efficacy in sputum macrophages in COPD. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 1166-1173.	1.5	47
192	Anti-Inflammatory Therapeutics in COPD: Past, Present, and Future. , 2013, , 191-213.		0
193	Rhinovirus infection causes steroid resistance in airway epithelium through nuclear factor κ B and c-Jun N-terminal kinase activation. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 1075-1085.e6.	1.5	80
194	Inhibition of LPS-induced airway neutrophilic inflammation in healthy volunteers with an oral CXCR2 antagonist. <i>Respiratory Research</i> , 2013, 14, 137.	1.4	64
195	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 347-365.	2.5	7,792
196	A role for M2 and M3 muscarinic receptors in the contraction of rat and human small airways. <i>European Journal of Pharmacology</i> , 2013, 702, 109-115.	1.7	26
197	Chronic obstructive pulmonary disease: important advances. <i>Lancet Respiratory Medicine</i> , the, 2013, 1, e7-e8.	5.2	6
198	Regulation of Wnt4 in chronic obstructive pulmonary disease. <i>FASEB Journal</i> , 2013, 27, 2367-2381.	0.2	32

#	ARTICLE	IF	CITATIONS
199	Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, 636-645.	1.5	569
200	Exhaled Nitric Oxide in Clinical Practice: Recent Advances and New Challenges. , 2013, , 231-241.		0
201	Theophylline. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 188, 901-906.	2.5	345
202	New anti-inflammatory targets for chronic obstructive pulmonary disease. <i>Nature Reviews Drug Discovery</i> , 2013, 12, 543-559.	21.5	332
203	S66â€¦Targeting anti-ageing molecule AMPK restores corticosteroid sensitivity in COPD. <i>Thorax</i> , 2013, 68, A36.1-A36.	2.7	0
204	Probiotics in the Management of Lung Diseases. <i>Mediators of Inflammation</i> , 2013, 2013, 1-10.	1.4	95
205	A Novel Macrolide Solithromycin Exerts Superior Anti-inflammatory Effect via NF- κ B Inhibition. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 345, 76-84.	1.3	100
206	Dysfunction of Endothelial Progenitor Cells from Smokers and Chronic Obstructive Pulmonary Disease Patients Due to Increased DNA Damage and Senescence. <i>Stem Cells</i> , 2013, 31, 2813-2826.	1.4	138
207	Importin β mediates glucocorticoid receptor nuclear import and is impaired by oxidative stress, leading to glucocorticoid insensitivity. <i>FASEB Journal</i> , 2013, 27, 4510-4519.	0.2	50
208	Decreased indoleamine 2,3-dioxygenase activity and IL-10/IL-17A ratio in patients with COPD. <i>Thorax</i> , 2013, 68, 330-337.	2.7	46
209	P184â€¦Macrophage phagocytosis in COPD patients at exacerbation compared to stable state. <i>Thorax</i> , 2013, 68, A159.1-A159.	2.7	1
210	S112â€¦HDAC activity in macrophages in experimental rhinovirus infection in COPD. <i>Thorax</i> , 2013, 68, A58.2-A59.	2.7	0
211	T5â€¦Circulating endothelial progenitor cells in smokers and patients with COPD are dysfunctional due to increased DNA damage and senescence. <i>Thorax</i> , 2013, 68, A2.3-A3.	2.7	1
212	Oxidative Stress in COPD. <i>Chest</i> , 2013, 144, 266-273.	0.4	556
213	Sputum Plasminogen Activator Inhibitor-1 Elevation by Oxidative Stress-Dependent Nuclear Factor- κ B Activation in COPD. <i>Chest</i> , 2013, 144, 515-521.	0.4	39
214	Toll-like Receptor 3 Stimulation Causes Corticosteroid-Refractory Airway Neutrophilia and Hyperresponsiveness in Mice. <i>Chest</i> , 2013, 144, 99-105.	0.4	48
215	Development of New Drugs for COPD. <i>Current Medicinal Chemistry</i> , 2013, 20, 1531-1540.	1.2	30
216	The Future of COPD. , 2013, , 77-92.		0

#	ARTICLE	IF	CITATIONS
217	COPD: inflammatory mechanisms and systemic consequences. , 2013, , 13-27.		0
218	New Drugs for Asthma. Seminars in Respiratory and Critical Care Medicine, 2012, 33, 685-694.	0.8	21
219	Rhinovirus Infection Induces Degradation of Antimicrobial Peptides and Secondary Bacterial Infection in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 1117-1124.	2.5	238
220	Addressing Unmet Medical Needs in COPD Management. , 2012, , .		0
221	Defect of Adaptation to Hypoxia in Patients With COPD Due to Reduction of Histone Deacetylase 7. Chest, 2012, 141, 1233-1242.	0.4	30
222	P253â€¦Association of Defective Monocyte-Derived Macrophage Phagocytosis with Clinical Phenotypes in Stable COPD. Thorax, 2012, 67, A175.2-A176.	2.7	0
223	Do inhaled corticosteroid/long-acting beta2-agonist fixed combinations provide superior clinical benefits compared with separate inhalers? A literature reappraisal. Allergy and Asthma Proceedings, 2012, 33, 140-144.	1.0	17
224	Corticosteroid insensitivity is reversed by formoterol via phosphoinositideâ€¦kinase inhibition. British Journal of Pharmacology, 2012, 167, 775-786.	2.7	55
225	Defective Phagocytosis in Airways Disease. Chest, 2012, 141, 1055-1062.	0.4	157
226	David Jack (1924â€¦2011) who revolutionised the treatment of asthma. Thorax, 2012, 67, 266-267.	2.7	4
227	Increased corticosteroid sensitivity by a long acting Î²2 agonist formoterol via Î²2 adrenoceptor independent protein phosphatase 2A activation. Pulmonary Pharmacology and Therapeutics, 2012, 25, 201-207.	1.1	43
228	Coordinated regulation of IL-4 and IL-13 expression in human T cells: 3C analysis for DNA looping. Biochemical and Biophysical Research Communications, 2012, 417, 996-1001.	1.0	12
229	Severe asthma: Advances in current management and future therapy. Journal of Allergy and Clinical Immunology, 2012, 129, 48-59.	1.5	151
230	Assessing and treating small airways disease in asthma and chronic obstructive pulmonary disease. Annals of Medicine, 2012, 44, 146-156.	1.5	81
231	Corticosteroids. Clinics in Chest Medicine, 2012, 33, 531-541.	0.8	34
232	Restoration of Corticosteroid Sensitivity by p38 Mitogen Activated Protein Kinase Inhibition in Peripheral Blood Mononuclear Cells from Severe Asthma. PLoS ONE, 2012, 7, e41582.	1.1	100
233	Therapy of Airway Disease. , 2012, , 387-393.		0
234	Autonomic Control of the Lower Airways. , 2012, , 201-204.		2

#	ARTICLE	IF	CITATIONS
235	Biology and Assessment of Airway Inflammation. , 2012, , 75-88.		3
236	Drugs for airway disease. Medicine, 2012, 40, 228-237.	0.2	5
237	COPD and Asthma: Effects Beyond the Respiratory System. Tanaffos, 2012, 11, 9.	0.5	1
238	Reduced denitration activity in peripheral lung of chronic obstructive pulmonary disease. Tanaffos, 2012, 11, 23-9.	0.5	5
239	Immunological Features of Chronic Obstructive Pulmonary Disease (COPD) Induced by Indoor Pollution and Cigarette Smoke. Tanaffos, 2012, 11, 6-17.	0.5	2
240	Triple inhalers for obstructive airways disease: will they be useful?. Expert Review of Respiratory Medicine, 2011, 5, 297-300.	1.0	21
241	The effects of an anti-IL-13 mAb on cytokine levels and nasal symptoms following nasal allergen challenge. Journal of Allergy and Clinical Immunology, 2011, 128, 800-807.e9.	1.5	59
242	C4 Drugs for the treatment of airway disease. , 2011, , 321-357.		1
243	Decreased histone deacetylase 2 impairs Nrf2 activation by oxidative stress. Biochemical and Biophysical Research Communications, 2011, 406, 292-298.	1.0	181
244	Comparison of Symbicort® versus Pulmicort® on steroid pharmacodynamic markers in asthma patients. Respiratory Medicine, 2011, 105, 1784-1789.	1.3	12
245	Correlation between Eicosanoids in Bronchoalveolar Lavage Fluid and in Exhaled Breath Condensate. Disease Markers, 2011, 30, 213-220.	0.6	28
246	Defects of Protein Phosphatase 2A Causes Corticosteroid Insensitivity in Severe Asthma. PLoS ONE, 2011, 6, e27627.	1.1	78
247	Hydrogen Peroxide in Exhaled Breath Condensate in Patients with Asthma. Chest, 2011, 140, 108-116.	0.4	64
248	Glucocorticosteroids: current and future directions. British Journal of Pharmacology, 2011, 163, 29-43.	2.7	405
249	Pathophysiology of allergic inflammation. Immunological Reviews, 2011, 242, 31-50.	2.8	281
250	Inflammation in COPD. Clinical Respiratory Journal, 2011, 5, 1-2.	0.6	6
251	New perspectives in pharmacological treatment of mild persistent asthma. Drug Discovery Today, 2011, 16, 1084-1091.	3.2	59
252	Long-acting fluticasone furoate has a superior pharmacological profile to fluticasone propionate in human respiratory cells. European Journal of Pharmacology, 2011, 670, 244-251.	1.7	57

#	ARTICLE	IF	CITATIONS
253	Chronic Obstructive Pulmonary Disease and Lung Cancer: A Lethal Association. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 866-867.	2.5	45
254	Unbalanced oxidant-induced DNA damage and repair in COPD: a link towards lung cancer. Thorax, 2011, 66, 521-527.	2.7	148
255	Oxidative Stress-induced Antibodies to Carbonyl-modified Protein Correlate with Severity of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 796-802.	2.5	159
256	Nortriptyline Reverses Corticosteroid Insensitivity by Inhibition of Phosphoinositide-3-Kinase- β . Journal of Pharmacology and Experimental Therapeutics, 2011, 337, 465-470.	1.3	77
257	Chronic Obstructive Pulmonary Disease and Lung Cancer: New Molecular Insights. Respiration, 2011, 81, 265-284.	1.2	213
258	Similarities and differences in inflammatory mechanisms of asthma and COPD. Breathe, 2011, 7, 229-238.	0.6	21
259	Biochemical Basis of Asthma Therapy. Journal of Biological Chemistry, 2011, 286, 32899-32905.	1.6	103
260	Denitrosylation of HDAC2 by targeting Nrf2 restores glucocorticosteroid sensitivity in macrophages from COPD patients. Journal of Clinical Investigation, 2011, 121, 4289-4302.	3.9	116
261	Osteoprotegerin in Sputum Is a Potential Biomarker in COPD. Chest, 2011, 140, 76-83.	0.4	14
262	p38 Mitogen-Activated Protein Kinase- β Inhibition by Long-Acting β_2 Adrenergic Agonists Reversed Steroid Insensitivity in Severe Asthma. Molecular Pharmacology, 2011, 80, 1128-1135.	1.0	66
263	Regulation of IL-17 in chronic inflammation in the human lung. Clinical Science, 2011, 120, 515-524.	1.8	39
264	Glucocorticosteroids: current and future directions. British Journal of Pharmacology, 2011, 163, 29-43.	2.7	34
265	Chemokine receptor CXCR2 antagonism to prevent airways inflammation. Drugs of the Future, 2011, 36, 465.	0.0	13
266	Targeting Histone Deacetylases in Chronic Obstructive Pulmonary Disease. , 2011, , 205-215.		0
267	The Future of COPD. , 2011, , 75-90.		1
268	Epidemiology, Risk Factors and Pathophysiology. , 2011, , 7-28.		0
269	Identification of Novel Therapeutic Targets in COPD. Tanaffos, 2011, 10, 9-14.	0.5	2
270	Epigenetics and chromatin remodeling play a role in lung disease. Tanaffos, 2011, 10, 7-16.	0.5	26

#	ARTICLE	IF	CITATIONS
271	Diagnostic Performance of an Electronic Nose, Fractional Exhaled Nitric Oxide, and Lung Function Testing in Asthma. <i>Chest</i> , 2010, 137, 790-796.	0.4	191
272	Rescue Treatment in Asthma: Response. <i>Chest</i> , 2010, 137, 240-241.	0.4	0
273	Treatment Effects of Low-Dose Theophylline Combined With an Inhaled Corticosteroid in COPD. <i>Chest</i> , 2010, 137, 1338-1344.	0.4	166
274	Is Exposure to Biomass Smoke the Biggest Risk Factor for COPD Globally?. <i>Chest</i> , 2010, 138, 3-6.	0.4	188
275	Inhaled Corticosteroids. <i>Pharmaceuticals</i> , 2010, 3, 514-540.	1.7	173
276	Exhaled carbon monoxide in asthmatics: a meta-analysis. <i>Respiratory Research</i> , 2010, 11, 50.	1.4	49
277	Involvement Of P38MAPK Gamma On Corticosteroid Refractory Airway Inflammation Induced By Tobacco Smoke In Mice. , 2010, , .		0
278	Theophylline. <i>Pharmaceuticals</i> , 2010, 3, 725-747.	1.7	86
279	Inhaled Corticosteroids in COPD: A Controversy. <i>Respiration</i> , 2010, 80, 89-95.	1.2	125
280	New Therapies for Chronic Obstructive Pulmonary Disease. <i>Medical Principles and Practice</i> , 2010, 19, 330-338.	1.1	69
281	Neutrophils Find Smoke Attractive. <i>Science</i> , 2010, 330, 40-41.	6.0	23
282	Targeting Phosphoinositide-3-Kinase- γ with Theophylline Reverses Corticosteroid Insensitivity in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 897-904.	2.5	321
283	Exhaled Nitric Oxide in Pulmonary Diseases. <i>Chest</i> , 2010, 138, 682-692.	0.4	347
284	What the Journal Would Like to Publish on Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 1-2.	2.5	9
285	Nitric Oxide Synthase Isoenzyme Expression and Activity in Peripheral Lung Tissue of Patients with Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 181, 21-30.	2.5	91
286	Chronic Obstructive Pulmonary Disease: Effects beyond the Lungs. <i>PLoS Medicine</i> , 2010, 7, e1000220.	3.9	139
287	Statins enhance the anti-inflammatory effects of inhaled corticosteroids in asthmatic patients through increased induction of indoleamine 2, 3-dioxygenase. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 126, 754-762.e1.	1.5	126
288	Mechanisms and resistance in glucocorticoid control of inflammation. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2010, 120, 76-85.	1.2	264

#	ARTICLE	IF	CITATIONS
289	New therapies for asthma: is there any progress?. Trends in Pharmacological Sciences, 2010, 31, 335-343.	4.0	195
290	Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulmonary Pharmacology and Therapeutics, 2010, 23, 165-171.	1.1	102
291	Comparison of inspiratory and expiratory resistance and reactance in patients with asthma and chronic obstructive pulmonary disease. Thorax, 2010, 65, 263-267.	2.7	115
292	New drugs and targets for asthma and COPD. Progress in Respiratory Research, 2010, , 3-23.	0.1	5
293	Genomics in the Evaluation and Management of Chronic Obstructive Pulmonary Disease. , 2010, , 603-615.		1
294	Oxidative/nitrosative stress selectively altered A _{2B} adenosine receptors in chronic obstructive pulmonary disease. FASEB Journal, 2010, 24, 1192-1204.	0.2	15
295	Measurement of 8-Isoprostane in Exhaled Breath Condensate. Methods in Molecular Biology, 2010, 594, 73-84.	0.4	30
296	Telomere Shortening in Alveolar Macrophages of Smokers and COPD Patients~!2010-02-18~!2010-03-05~!2010-04-15~!. The Open Pathology Journal, 2010, 4, 23-29.	1.0	9
297	Signal Transduction Pathways Involved in Glucocorticoid Actions. , 2010, , 289-309.		0
298	Pharmacologic Principles. , 2010, , 159-199.		0
299	Genomic Aspects of Chronic Obstructive Pulmonary Disease. , 2009, , 1098-1109.		0
300	The Cytokine Network in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory Cell and Molecular Biology, 2009, 41, 631-638.	1.4	321
301	Hypoxia-inducible Factor 1 α Induces Corticosteroid-insensitive Inflammation via Reduction of Histone Deacetylase-2 Transcription. Journal of Biological Chemistry, 2009, 284, 36047-36054.	1.6	49
302	A protein deacetylase SIRT1 is a negative regulator of metalloproteinase ϵ . FASEB Journal, 2009, 23, 2810-2819.	0.2	205
303	COPD as a Disease of Accelerated Lung Aging. Chest, 2009, 135, 173-180.	0.4	514
304	Peroxynitrite Elevation in Exhaled Breath Condensate of COPD and Its Inhibition by Fudosteine. Chest, 2009, 135, 1513-1520.	0.4	78
305	A DPOC como uma doen \tilde{a} sa de envelhecimento acelerado**Chest Translating Basic Research Into Clinical Practice 2009; 135:173-180. Revista Portuguesa De Pneumologia, 2009, 15, 743-746.	0.7	7
306	Targeting the Epigenome in the Treatment of Asthma and Chronic Obstructive Pulmonary Disease. Proceedings of the American Thoracic Society, 2009, 6, 693-696.	3.5	130

#	ARTICLE	IF	CITATIONS
307	Suppression of GATA-3 Nuclear Import and Phosphorylation: A Novel Mechanism of Corticosteroid Action in Allergic Disease. <i>PLoS Medicine</i> , 2009, 6, e1000076.	3.9	83
308	Burden and Pathogenesis of Chronic Obstructive Pulmonary Disease. <i>Proceedings of the American Thoracic Society</i> , 2009, 6, 524-526.	3.5	113
309	Activation of NF- κ B transcription factor in asthma death. <i>Histopathology</i> , 2009, 54, 507-509.	1.6	19
310	MUC5AC expression is increased in bronchial submucosal glands of stable COPD patients. <i>Histopathology</i> , 2009, 55, 321-331.	1.6	83
311	Bronchodilatory Effect of the PPAR- γ Agonist Rosiglitazone in Smokers With Asthma. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 86, 49-53.	2.3	85
312	Nitration of distinct tyrosine residues causes inactivation of histone deacetylase 2. <i>Biochemical and Biophysical Research Communications</i> , 2009, 384, 366-371.	1.0	140
313	Alternative mechanisms for tiotropium. <i>Pulmonary Pharmacology and Therapeutics</i> , 2009, 22, 533-542.	1.1	109
314	Der p 1 suppresses indoleamine 2, 3-dioxygenase in dendritic cells from house dust mite-sensitive patients with asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2009, 123, 239-248.	1.5	36
315	Pathophysiology of COPD. , 2009, , 425-442.		2
316	Histone deacetylase-2 and airway disease. <i>Therapeutic Advances in Respiratory Disease</i> , 2009, 3, 235-243.	1.0	117
317	Neural and Humoral Control of the Airways. , 2009, , 381-397.		0
318	Pathophysiology of Asthma. , 2009, , 399-423.		0
319	Anticholinergic Bronchodilators. , 2009, , 615-626.		0
320	Mediator Antagonists. , 2009, , 655-662.		0
321	Future Therapies. , 2009, , 737-749.		0
322	Role of HDAC2 in the Pathophysiology of COPD. <i>Annual Review of Physiology</i> , 2009, 71, 451-464.	5.6	281
323	A Randomized, Double-blind, Placebo-controlled Study of Tumor Necrosis Factor- α Blockade in Severe Persistent Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 179, 549-558.	2.5	444
324	Inhibition of PI3K Restores Glucocorticoid Function in Smoking-induced Airway Inflammation in Mice. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 179, 542-548.	2.5	222

#	ARTICLE	IF	CITATIONS
325	A DPOC como uma doena de envelhecimento acelerado. Revista Portuguesa De Pneumologia, 2009, 15, 743-746.	0.7	4
326	Glucocorticoid resistance in inflammatory diseases. Lancet, The, 2009, 373, 1905-1917.	6.3	850
327	Chronic obstructive pulmonary disease in non-smokers. Lancet, The, 2009, 374, 733-743.	6.3	1,080
328	New drugs for exacerbations of chronic obstructive pulmonary disease. Lancet, The, 2009, 374, 744-755.	6.3	89
329	Chronic obstructive pulmonary disease in non-smokers – Authors' reply. Lancet, The, 2009, 374, 1965-1966.	6.3	3
330	Systemic manifestations and comorbidities of COPD. European Respiratory Journal, 2009, 33, 1165-1185.	3.1	1,365
331	Effects of Aminoguanidine, an Inhibitor of Inducible Nitric Oxide Synthase, on Nitric Oxide Production and Its Metabolites in Healthy Control Subjects, Healthy Smokers, and COPD Patients. Chest, 2009, 135, 353-367.	0.4	48
332	Rescue Treatment in Asthma. Chest, 2009, 135, 1628-1633.	0.4	36
333	Novel mechanisms and new therapies for chronic obstructive pulmonary disease. Therapy: Open Access in Clinical Medicine, 2009, 6, 795-804.	0.2	1
334	COPD. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2009, 19, 10-20.	2.5	76
335	Chronic obstructive pulmonary disease: reasons for optimism. Therapy: Open Access in Clinical Medicine, 2009, 6, 769-770.	0.2	1
336	Pathophysiology of Allergic Inflammation. , 2009, , 455-472.		1
337	Immunology of asthma and chronic obstructive pulmonary disease. Nature Reviews Immunology, 2008, 8, 183-192.	10.6	1,147
338	Exhaled 8-isoprostane and prostaglandin E2 in patients with stable and unstable cystic fibrosis – This work was performed at the Catholic University of the Sacred Heart, Rome, Italy, and Ospedale Pediatrico Bambino Gesù, Rome, Italy. This work was funded by the Catholic University of the Sacred Heart. Free Radical Biology and Medicine, 2008, 45, 913-919.	1.3	79
339	Drugs for airway disease. Medicine, 2008, 36, 181-190.	0.2	8
340	Future Treatments for Chronic Obstructive Pulmonary Disease and Its Comorbidities. Proceedings of the American Thoracic Society, 2008, 5, 857-864.	3.5	65
341	Sputum indoleamine-2, 3-dioxygenase activity is increased in asthmatic airways by using inhaled corticosteroids. Journal of Allergy and Clinical Immunology, 2008, 121, 43-50.	1.5	47
342	Molecular Mechanisms of Corticosteroid Resistance. Chest, 2008, 134, 394-401.	0.4	214

#	ARTICLE	IF	CITATIONS
343	Avancées thérapeutiques pouvant modifier l'évolution clinique de la BPCO. <i>Revue Des Maladies Respiratoires</i> , 2008, 25, 16-20.	1.7	0
344	Optimized Dialysis and Protease Inhibition of Sputum Dithiothreitol Supernatants. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 177, 132-141.	2.5	26
345	Importance of inhaler devices in the management of airway disease. <i>Respiratory Medicine</i> , 2008, 102, 10-19.	1.3	256
346	Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. <i>Respiratory Medicine</i> , 2008, 102, 593-604.	1.3	503
347	Small airways: an important but neglected target in the treatment of obstructive airway diseases. <i>Trends in Pharmacological Sciences</i> , 2008, 29, 340-345.	4.0	67
348	Oxidative stress modulates theophylline effects on steroid responsiveness. <i>Biochemical and Biophysical Research Communications</i> , 2008, 377, 797-802.	1.0	49
349	Frontrunners in novel pharmacotherapy of COPD. <i>Current Opinion in Pharmacology</i> , 2008, 8, 300-307.	1.7	46
350	Increasing Doses of Inhaled Corticosteroids Compared to Adding Long-Acting Inhaled β_2 -Agonists in Achieving Asthma Control. <i>Chest</i> , 2008, 134, 1192-1199.	0.4	68
351	Rapid Effect of Inhaled Ciclesonide in Asthma. <i>Chest</i> , 2008, 134, 740-745.	0.4	39
352	Future therapies for chronic obstructive pulmonary disease. <i>Journal of Organ Dysfunction</i> , 2008, 4, 66-70.	0.3	1
353	Different Mitogen-Activated Protein Kinase-Dependent Cytokine Responses in Cells of the Monocyte Lineage. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 324, 306-312.	1.3	63
354	Pharmacological Characterization of Indacaterol, a Novel Once Daily Inhaled β_2 Adrenoceptor Agonist, on Small Airways in Human and Rat Precision-Cut Lung Slices. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 324, 270-275.	1.3	107
355	A Blood Test for Lung Fibrosis. <i>PLoS Medicine</i> , 2008, 5, e98.	3.9	1
356	Role of GATA-3 in Allergic Diseases. <i>Current Molecular Medicine</i> , 2008, 8, 330-334.	0.6	83
357	Emerging Pharmacotherapies for COPD. <i>Chest</i> , 2008, 134, 1278-1286.	0.4	105
358	Defective Antioxidant Gene Regulation in COPD: A Case for Broccoli. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 178, 552-554.	2.5	9
359	Steroid-Resistant Neutrophilic Inflammation in a Mouse Model of an Acute Exacerbation of Asthma. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2008, 39, 543-550.	1.4	121
360	Potential Novel Therapies for Chronic Obstructive Pulmonary Disease. <i>Novartis Foundation Symposium</i> , 2008, , 255-272.	1.2	18

#	ARTICLE	IF	CITATIONS
361	CXCR3 and CCR5 Chemokines in Induced Sputum From Patients With COPD. <i>Chest</i> , 2008, 133, 26-33.	0.4	140
362	Current and Future Therapies for Airway Mucus Hypersecretion. <i>Novartis Foundation Symposium</i> , 2008, , 237-253.	1.2	31
363	The cytokine network in asthma and chronic obstructive pulmonary disease. <i>Journal of Clinical Investigation</i> , 2008, 118, 3546-3556.	3.9	779
364	Î2-Agonists, Anticholinergics, and Other Nonsteroid Drugs. , 2008, , 471-482.		0
365	Overcoming steroid insensitivity in smoking asthmatics. <i>Current Opinion in Investigational Drugs</i> , 2008, 9, 470-7.	2.3	11
366	Repression of Inflammatory Gene Expression in Human Pulmonary Epithelial Cells by Small-Molecule ÎB Kinase Inhibitors. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 321, 734-742.	1.3	96
367	The Role of ÎB Kinase 2, but Not Activation of NF-ÎB, in the Release of CXCR3 Ligands from IFN-Î3-Stimulated Human Bronchial Epithelial Cells. <i>Journal of Immunology</i> , 2007, 179, 6237-6245.	0.4	43
368	Chronic Obstructive Pulmonary Disease: A Growing but Neglected Global Epidemic. <i>PLoS Medicine</i> , 2007, 4, e112.	3.9	129
369	Effect of an Inducible Nitric Oxide Synthase Inhibitor on Differential Flow-Exhaled Nitric Oxide in Asthmatic Patients and Healthy Volunteers. <i>Chest</i> , 2007, 132, 581-588.	0.4	40
370	Prevention of Death in COPD. <i>New England Journal of Medicine</i> , 2007, 356, 2211-2214.	13.9	46
371	Inflammation, Oxidative Stress and Systemic Effects in Mild Chronic Obstructive Pulmonary Disease. <i>International Journal of Immunopathology and Pharmacology</i> , 2007, 20, 753-763.	1.0	54
372	New aspects of chronic obstructive pulmonary disease. <i>Journal of Organ Dysfunction</i> , 2007, 3, 240-249.	0.3	0
373	Normal Bronchial Blood Flow in COPD Is Unaffected by Inhaled Corticosteroids and Correlates With Exhaled Nitric Oxide. <i>Chest</i> , 2007, 131, 1075-1081.	0.4	16
374	Differential Flow Analysis of Exhaled Nitric Oxide in Patients With Asthma of Differing Severity. <i>Chest</i> , 2007, 131, 1353-1362.	0.4	72
375	Loss of Control of Asthma Following Inhaled Corticosteroid Withdrawal Is Associated With Increased Sputum Interleukin-8 and Neutrophils. <i>Chest</i> , 2007, 132, 98-105.	0.4	59
376	Regulation of Th2 Cytokine Genes by p38 MAPK-Mediated Phosphorylation of GATA-3. <i>Journal of Immunology</i> , 2007, 178, 2491-2498.	0.4	146
377	The problem of cough and development of novel antitussives. <i>Pulmonary Pharmacology and Therapeutics</i> , 2007, 20, 416-422.	1.1	37
378	Unexpected Failure of Anti-“Tumor Necrosis Factor Therapy in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007, 175, 866-867.	2.5	41

#	ARTICLE	IF	CITATIONS
379	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007, 176, 532-555.	2.5	5,801
380	Glucocorticosteroids for Asthma. <i>NeuroImmune Biology</i> , 2007, , 359-381.	0.2	1
381	Using a combination inhaler (budesonide plus formoterol) as rescue therapy improves asthma control. <i>BMJ: British Medical Journal</i> , 2007, 335, 513-513.	2.4	26
382	Introducing Expert Review of Respiratory Medicine. <i>Expert Review of Respiratory Medicine</i> , 2007, 1, 1-2.	1.0	2
383	Oxidative Stress Regulates IL-4 Gene Expression In Mast Cells Through Reduction Of Histone Deacetylase (HDAC). <i>Journal of Allergy and Clinical Immunology</i> , 2007, 119, S138.	1.5	1
384	New molecular targets for the treatment of neutrophilic diseases. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 119, 1055-1062.	1.5	164
385	Alteration of Adenosine Receptors in Patients with Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 398-406.	2.5	101
386	The Effects of a Monoclonal Antibody Directed against Tumor Necrosis Factor- α in Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 174, 753-762.	2.5	270
387	Pulmonary Biomarkers in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 174, 6-14.	2.5	255
388	Beclometasone Dipropionate/Formoterol in an HFA-Propelled Pressurised Metered-Dose Inhaler. <i>Drugs</i> , 2006, 66, 1484-1485.	4.9	0
389	Pharmacology of airways and vessels in lung slices in situ: role of endogenous dilator hormones. <i>Respiratory Research</i> , 2006, 7, 111.	1.4	26
390	CORTICOSTEROIDS Therapy. , 2006, , 576-581.		0
391	Cytokine production by bronchoalveolar lavage T lymphocytes in chronic obstructive pulmonary disease. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 117, 1484-1492.	1.5	97
392	Effects of a leukotriene receptor antagonist on exhaled leukotriene E4 and prostanoids in children with asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 118, 347-353.	1.5	94
393	Expression of nonmuscle cofilin-1 and steroid responsiveness in severe asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 118, 1090-1096.	1.5	19
394	Isoprostanes and asthma. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2006, 3, 287-292.	0.5	8
395	New therapies for asthma. <i>Trends in Molecular Medicine</i> , 2006, 12, 515-520.	3.5	49
396	Chemokine receptors as therapeutic targets in chronic obstructive pulmonary disease. <i>Trends in Pharmacological Sciences</i> , 2006, 27, 546-553.	4.0	120

#	ARTICLE	IF	CITATIONS
397	BRONCHODILATORS Theophylline. , 2006, , 292-296.		0
398	Reduced Histone Deacetylase in COPD. Chest, 2006, 129, 151-155.	0.4	142
399	Beyond the Dutch Hypothesis. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 1057-1057.	2.5	0
400	Rebuttal by Dr. Barnes. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 974-974.	2.5	3
401	Drugs for asthma. British Journal of Pharmacology, 2006, 147, S297-S303.	2.7	95
402	How corticosteroids control inflammation: Quintiles Prize Lecture 2005. British Journal of Pharmacology, 2006, 148, 245-254.	2.7	650
403	Transcription factors in airway diseases. Laboratory Investigation, 2006, 86, 867-872.	1.7	102
404	Corticosteroids: The drugs to beat. European Journal of Pharmacology, 2006, 533, 2-14.	1.7	226
405	Novel signal transduction modulators for the treatment of airway diseases. , 2006, 109, 238-245.		52
406	Exhaled Biomarkers. Chest, 2006, 130, 1541-1546.	0.4	209
407	Future treatments. BMJ: British Medical Journal, 2006, 333, 246-248.	2.4	11
408	Treatment with (R)-Albuterol Has No Advantage over Racemic Albuterol. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 969-972.	2.5	29
409	Relative Corticosteroid Insensitivity of Peripheral Blood Mononuclear Cells in Severe Asthma. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 134-141.	2.5	247
410	Measurement of Bronchial and Alveolar Nitric Oxide Production in Normal Children and Children with Asthma. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 260-267.	2.5	145
411	Validation of the Anti-Inflammatory Properties of Small-Molecule I κ B Kinase (IKK)-2 Inhibitors by Comparison with Adenoviral-Mediated Delivery of Dominant-Negative IKK1 and IKK2 in Human Airways Smooth Muscle. Molecular Pharmacology, 2006, 70, 697-705.	1.0	71
412	Treatment of airway mucus hypersecretion. Annals of Medicine, 2006, 38, 116-125.	1.5	187
413	Histone deacetylase mediated deacetylation of the glucocorticoid receptor enables NF- κ B suppression. Journal of Experimental Medicine, 2006, 203, 7-13.	4.2	581
414	Against the Dutch Hypothesis: Asthma and Chronic Obstructive Pulmonary Disease Are Distinct Diseases. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 240-243.	2.5	97

#	ARTICLE	IF	CITATIONS
415	Generating Monodisperse Pharmacological Aerosols Using the Spinning-top Aerosol Generator. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2006, 19, 245-253.	1.2	4
416	Corticosteroid effects on cell signalling. <i>European Respiratory Journal</i> , 2006, 27, 413-426.	3.1	348
417	IL-1 β and TNF- α Regulation of the Adenosine Receptor (A2A) Expression: Differential Requirement for NF- κ B Binding to the Proximal Promoter. <i>Journal of Immunology</i> , 2006, 177, 7173-7183.	0.4	72
418	NF- κ B and Activator Protein 1 Response Elements and the Role of Histone Modifications in IL-1 β -Induced TGF- β 1 Gene Transcription. <i>Journal of Immunology</i> , 2006, 176, 603-615.	0.4	160
419	Receptor heterodimerization: a new level of cross-talk. <i>Journal of Clinical Investigation</i> , 2006, 116, 1210-1212.	3.9	45
420	Biology and Assessment of Airway Inflammation. , 2006, , 65-74.		0
421	CHRONIC OBSTRUCTIVE PULMONARY DISEASE Overview. , 2006, , 429-439.		1
422	Glycopyrrolate Causes Prolonged Bronchoprotection and Bronchodilatation in Patients With Asthma. <i>Chest</i> , 2005, 128, 1974-1979.	0.4	72
423	Effects of Aerosolized Adenosine 5 α -Triphosphate vs Adenosine 5 α -Monophosphate on Dyspnea and Airway Caliber in Healthy Nonsmokers and Patients With Asthma. <i>Chest</i> , 2005, 128, 1905-1909.	0.4	84
424	Formoterol Attenuates Neutrophilic Airway Inflammation in Asthma. <i>Chest</i> , 2005, 128, 1936-1942.	0.4	68
425	Chronic Idiopathic Cough. <i>Chest</i> , 2005, 127, 1710-1713.	0.4	213
426	Validation of IKK β as therapeutic target in airway inflammatory disease by adenoviral-mediated delivery of dominant-negative IKK β to pulmonary epithelial cells. <i>British Journal of Pharmacology</i> , 2005, 145, 114-122.	2.7	39
427	Regional Lung Deposition and Bronchodilator Response as a Function of β 2-Agonist Particle Size. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005, 172, 1497-1504.	2.5	482
428	A Single Inhaler for Asthma?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005, 171, 95-96.	2.5	13
429	Glucocorticoid Receptor Nuclear Translocation in Airway Cells after Inhaled Combination Therapy. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005, 172, 704-712.	2.5	212
430	Targeting histone deacetylase 2 in chronic obstructive pulmonary disease treatment. <i>Expert Opinion on Therapeutic Targets</i> , 2005, 9, 1111-1121.	1.5	45
431	Redox Regulation of Histone Deacetylases and Glucocorticoid-Mediated Inhibition of the Inflammatory Response. <i>Antioxidants and Redox Signaling</i> , 2005, 7, 144-152.	2.5	67
432	Theobromine inhibits sensory nerve activation and cough. <i>FASEB Journal</i> , 2005, 19, 1-16.	0.2	98

#	ARTICLE	IF	CITATIONS
433	Resveratrol, an extract of red wine, inhibits lipopolysaccharide induced airway neutrophilia and inflammatory mediators through an NF- κ B-independent mechanism. <i>FASEB Journal</i> , 2005, 19, 1-22.	0.2	153
434	Inflammatory Response to Sputum Induction Measured by Exhaled Markers. <i>Respiration</i> , 2005, 72, 594-599.	1.2	19
435	We are retracting the article entitled "Emerging Targets for COPD Therapy" by Peter J. Barnes published in <i>Current Drug Targets Inflammation & Allergy</i> . 2005 Dec;4(6):675-683. <i>Inflammation and Allergy: Drug Targets</i> , 2005, 4, 675-683.	3.1	10
436	Histone Deacetylation: An Important Mechanism in Inflammatory Lung Diseases. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2005, 2, 445-455.	0.7	119
437	Achieving asthma control. <i>Current Medical Research and Opinion</i> , 2005, 21, S5-S9.	0.9	42
438	Theophylline in Chronic Obstructive Pulmonary Disease: New Horizons. <i>Proceedings of the American Thoracic Society</i> , 2005, 2, 334-339.	3.5	121
439	5-Azacytidine suppresses RNA polymerase II recruitment to the SLPI gene. <i>Biochemical and Biophysical Research Communications</i> , 2005, 331, 93-99.	1.0	18
440	Histamine levels following adenosine monophosphate challenge. <i>Respiratory Medicine</i> , 2005, 99, 516.	1.3	0
441	Sputum matrix metalloproteases: comparison between chronic obstructive pulmonary disease and asthma. <i>Respiratory Medicine</i> , 2005, 99, 703-710.	1.3	122
442	Correlation of exhaled breath temperature with bronchial blood flow in asthma. <i>Respiratory Research</i> , 2005, 6, 15.	1.4	80
443	Exhaled 8-isoprostane in childhood asthma. <i>Respiratory Research</i> , 2005, 6, 79.	1.4	75
444	Histone acetylation and deacetylation: importance in inflammatory lung diseases. <i>European Respiratory Journal</i> , 2005, 25, 552-563.	3.1	504
445	Nitrosative stress in the bronchial mucosa of severe chronic obstructive pulmonary disease. <i>Journal of Allergy and Clinical Immunology</i> , 2005, 116, 1028-1035.	1.5	127
446	Molecular Mechanisms and Cellular Effects of Glucocorticosteroids. <i>Immunology and Allergy Clinics of North America</i> , 2005, 25, 451-468.	0.7	126
447	Decreased Histone Deacetylase Activity in Chronic Obstructive Pulmonary Disease. <i>New England Journal of Medicine</i> , 2005, 352, 1967-1976.	13.9	892
448	Drugs for the treatment of asthma and COPD. , 2005, , 281-344.		3
449	Autonomic Control of Airways. , 2004, , 130-133.		0
450	Mitogen-Activated Protein Kinase Modulation of Nuclear Factor- κ B-Induced Granulocyte Macrophage-Colony-Stimulating Factor Release from Human Alveolar Macrophages. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2004, 30, 342-349.	1.4	39

#	ARTICLE	IF	CITATIONS
451	Small Airways in COPD. <i>New England Journal of Medicine</i> , 2004, 350, 2635-2637.	13.9	103
452	Glucocorticoids: Effects on Gene Transcription. <i>Proceedings of the American Thoracic Society</i> , 2004, 1, 247-254.	3.5	138
453	Glucocorticoid Inhibition of Granulocyte Macrophageâ€“Colony-Stimulating Factor from T cells Is Independent of Control by Nuclear Factor- κ B and Conserved Lymphokine Element O. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2004, 30, 555-563.	1.4	42
454	Corticosteroid Resistance in Airway Disease. <i>Proceedings of the American Thoracic Society</i> , 2004, 1, 264-268.	3.5	113
455	Anti-inflammatory effects of resveratrol in lung epithelial cells: molecular mechanisms. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2004, 287, L774-L783.	1.3	297
456	Parameters associated with persistent airflow obstruction in chronic severe asthma. <i>European Respiratory Journal</i> , 2004, 24, 122-128.	3.1	208
457	Distribution of Receptor Targets in the Lung. <i>Proceedings of the American Thoracic Society</i> , 2004, 1, 345-351.	3.5	160
458	Exhaled Nitric Oxide and Hydrogen Peroxide Concentrations in Asthmatic Smokers. <i>Respiration</i> , 2004, 71, 463-468.	1.2	72
459	Inhibitors of Protein Kinase C (PKC) Prevent Activated Transcription. <i>Journal of Biological Chemistry</i> , 2004, 279, 18457-18466.	1.6	73
460	Histone Acetylase and Deacetylase Activity in Alveolar Macrophages and Blood Mononocytes in Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 170, 141-147.	2.5	237
461	Specific CXC but not CC chemokines cause elevated monocyte migration in COPD: a role for CXCR2. <i>Journal of Leukocyte Biology</i> , 2004, 76, 441-450.	1.5	144
462	ICAM-1 expression is highly NF- κ B-dependent in A549 cells. <i>FEBS Journal</i> , 2004, 271, 785-791.	0.2	46
463	Differential effects of RU486 reveal distinct mechanisms for glucocorticoid repression of prostaglandin E2 release. <i>FEBS Journal</i> , 2004, 271, 4042-4052.	0.2	44
464	Nuclear factor- κ B does not mediate the inhibitory effects of dexamethasone on granulocyte-macrophage colony-stimulating factor expression. <i>Immunology</i> , 2004, 111, 430-434.	2.0	4
465	New drugs for asthma. <i>Nature Reviews Drug Discovery</i> , 2004, 3, 831-844.	21.5	179
466	Alveolar Macrophages as Orchestrators of COPD. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2004, 1, 59-70.	0.7	273
467	The role of anticholinergics in chronic obstructive pulmonary disease. <i>The American Journal of Medicine: Supplement</i> , 2004, 117, 24-32.	1.7	51
468	Theophylline Restores Histone Deacetylase Activity and Steroid Responses in COPD Macrophages. <i>Journal of Experimental Medicine</i> , 2004, 200, 689-695.	4.2	442

#	ARTICLE	IF	CITATIONS
469	Discovery of BRL 50481 [3-(N,N-dimethylsulfonamido)-4-methyl-nitrobenzene], a Selective Inhibitor of Phosphodiesterase 7: In Vitro Studies in Human Monocytes, Lung Macrophages, and CD8+ T-Lymphocytes. <i>Molecular Pharmacology</i> , 2004, 66, 1679-1689.	1.0	160
470	Defective glucocorticoid receptor nuclear translocation and altered histone acetylation patterns in glucocorticoid-resistant patients. <i>Journal of Allergy and Clinical Immunology</i> , 2004, 113, 1100-1108.	1.5	194
471	Effects of inhaled corticosteroids on exhaled leukotrienes and prostanoids in asthmatic children. <i>Journal of Allergy and Clinical Immunology</i> , 2004, 114, 761-767.	1.5	121
472	Characterization of T Lymphocytes in Chronic Obstructive Pulmonary Disease. <i>PLoS Medicine</i> , 2004, 1, e20.	3.9	67
473	STAT4 activation in smokers and patients with chronic obstructive pulmonary disease. <i>European Respiratory Journal</i> , 2004, 24, 78-85.	3.1	120
474	Isoprostanes: markers and mediators of oxidative stress. <i>FASEB Journal</i> , 2004, 18, 1791-1800.	0.2	642
475	Add-on therapy options in asthma not adequately controlled by inhaled corticosteroids: a comprehensive review. <i>Respiratory Research</i> , 2004, 5, 17.	1.4	55
476	Effects of Corticosteroids on Noninvasive Biomarkers of Inflammation in Asthma and Chronic Obstructive Pulmonary Disease. <i>Proceedings of the American Thoracic Society</i> , 2004, 1, 191-199.	3.5	58
477	Mediators of Chronic Obstructive Pulmonary Disease. <i>Pharmacological Reviews</i> , 2004, 56, 515-548.	7.1	604
478	The Role of Oxidative Stress in Chronic Obstructive Pulmonary Disease. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2004, 1, 255-277.	0.7	122
479	COPD: is there light at the end of the tunnel?. <i>Current Opinion in Pharmacology</i> , 2004, 4, 263-272.	1.7	36
480	Oxidative stress reduces histone deacetylase 2 activity and enhances IL-8 gene expression: role of tyrosine nitration. <i>Biochemical and Biophysical Research Communications</i> , 2004, 315, 240-245.	1.0	341
481	Effect of cigarette smoking on haem-oxygenase expression in alveolar macrophages. <i>Respiratory Medicine</i> , 2004, 98, 530-535.	1.3	7
482	Adenosine 5â€²-monophosphate increases levels of leukotrienes in breath condensate in asthma. <i>Respiratory Medicine</i> , 2004, 98, 651-655.	1.3	23
483	Asthma guidelines: recommendations versus reality. <i>Respiratory Medicine</i> , 2004, 98, S1-S7.	1.3	13
484	The size of the problem of managing asthma. <i>Respiratory Medicine</i> , 2004, 98, S4-S8.	1.3	32
485	Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. <i>Lancet, The</i> , 2004, 363, 731-733.	6.3	364
486	COPDâ€™a neglected disease. <i>Lancet, The</i> , 2004, 364, 564-565.	6.3	54

#	ARTICLE	IF	CITATIONS
487	Prospects for new drugs for chronic obstructive pulmonary disease. <i>Lancet, The</i> , 2004, 364, 985-996.	6.3	176
488	Theophylline: Mechanism of action and use in asthma and chronic obstructive pulmonary disease. <i>Drugs of Today</i> , 2004, 40, 55.	2.4	39
489	New drugs for COPD based on advances in pathophysiology. , 2004, , 189-226.		0
490	Oxidative Stress in COPD. , 2004, , 61-74.		0
491	Exhaled Breath Condensate. , 2004, , 1-9.		4
492	Nitric oxide, nitrotyrosine, and nitric oxide modulators in asthma and chronic obstructive pulmonary disease. <i>Current Allergy and Asthma Reports</i> , 2003, 3, 121-129.	2.4	85
493	Drugs for airway disease. <i>Medicine</i> , 2003, 31, 44-51.	0.2	0
494	Therapy of chronic obstructive pulmonary disease. , 2003, 97, 87-94.		44
495	A system for the production and delivery of monodisperse salbutamol aerosols to the lungs. <i>International Journal of Pharmaceutics</i> , 2003, 254, 243-253.	2.6	24
496	Cytokine-directed therapies in asthma. <i>Allergology International</i> , 2003, 52, 53-63.	1.4	5
497	Evidence for post-transcriptional regulation of interleukin-5 by dexamethasone. <i>Immunology</i> , 2003, 109, 527-535.	2.0	17
498	Inhibition of guinea-pig and human sensory nerve activity and the cough reflex in guinea-pigs by cannabinoid (CB2) receptor activation. <i>British Journal of Pharmacology</i> , 2003, 140, 261-268.	2.7	83
499	Regulation of eosinophil apoptosis by nitric oxide: Role of c-Jun-N-terminal kinase and signal transducer and activator of transcription 5. <i>Journal of Allergy and Clinical Immunology</i> , 2003, 112, 93-101.	1.5	49
500	Theophylline. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2003, 167, 813-818.	2.5	402
501	Chronic obstructive pulmonary disease: molecular and cellular mechanisms. <i>European Respiratory Journal</i> , 2003, 22, 672-688.	3.1	1,174
502	IL-1 β -dependent activation of NF- κ B mediates PGE2 release via the expression of cyclooxygenase-2 and microsomal prostaglandin E synthase. <i>FEBS Letters</i> , 2003, 547, 75-79.	1.3	92
503	The effect of oxidative stress on histone acetylation and IL-8 release. <i>Biochemical and Biophysical Research Communications</i> , 2003, 301, 572-577.	1.0	112
504	High levels of interleukin-6 in the exhaled breath condensate of patients with COPD. <i>Respiratory Medicine</i> , 2003, 97, 1299-1302.	1.3	143

#	ARTICLE	IF	CITATIONS
505	Cytokine-directed therapies for the treatment of chronic airway diseases. Cytokine and Growth Factor Reviews, 2003, 14, 511-522.	3.2	93
506	Anti-leukotrienes: here to stay?. Current Opinion in Pharmacology, 2003, 3, 257-263.	1.7	19
507	Long-acting β_2 -adrenoceptor agonists or tiotropium bromide for patients with COPD: is combination therapy justified?. Current Opinion in Pharmacology, 2003, 3, 270-276.	1.7	38
508	New Concepts in Chronic Obstructive Pulmonary Disease. Annual Review of Medicine, 2003, 54, 113-129.	5.0	245
509	Slower rise of exhaled breath temperature in chronic obstructive pulmonary disease. European Respiratory Journal, 2003, 21, 439-443.	3.1	29
510	Increased inflammatory markers in the exhaled breath condensate of cigarette smokers. European Respiratory Journal, 2003, 21, 589-593.	3.1	124
511	Xanthine oxidase inhibition reduces reactive nitrogen species production in COPD airways. European Respiratory Journal, 2003, 22, 457-461.	3.1	40
512	Reproducibility of exhaled nitric oxide measurements in healthy and asthmatic adults and children. European Respiratory Journal, 2003, 21, 433-438.	3.1	277
513	A selective inhibitor of inducible nitric oxide synthase inhibits exhaled breath nitric oxide in healthy volunteers and asthmatics. FASEB Journal, 2003, 17, 1298-1300.	0.2	193
514	Nasal nitric oxide measurements for the screening of primary ciliary dyskinesia. European Respiratory Journal, 2003, 21, 43-47.	3.1	140
515	Effects of bronchodilator particle size in asthmatic patients using monodisperse aerosols. Journal of Applied Physiology, 2003, 95, 2106-2112.	1.2	80
516	How To Design a Negative Study. Chest, 2003, 123, 656.	0.4	0
517	Impaired Inhibition by Dexamethasone of Cytokine Release by Alveolar Macrophages from Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 24-31.	2.5	281
518	Increased Leukotriene B ₄ and Interleukin-6 in Exhaled Breath Condensate in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 1109-1112.	2.5	129
519	Interleukin-6, Obstructive Sleep Apnea, and Obesity. Chest, 2003, 124, 1622-1623.	0.4	0
520	Increased Exhaled 8-Isoprostane in Childhood Asthma. Chest, 2003, 124, 25-31.	0.4	134
521	How Do Corticosteroids Work in Asthma?. Annals of Internal Medicine, 2003, 139, 359.	2.0	300
522	Nitric Oxide Metabolites Are Not Reduced in Exhaled Breath Condensate of Patients With Primary Ciliary Dyskinesia*. Chest, 2003, 124, 633-638.	0.4	48

#	ARTICLE	IF	CITATIONS
523	Neurogenic inflammation in the airways. <i>NeuroImmune Biology</i> , 2003, , 437-449.	0.2	6
524	Neutrophil Chemotactic Activity of Sputum From Patients With COPD. <i>Chest</i> , 2003, 123, 1240-1247.	0.4	217
525	Glucocorticosteroids. , 2003, , 32-55.		0
526	Mitogen-activated protein kinases mediate peroxynitrite-induced cell death in human bronchial epithelial cells. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2003, 284, L1112-L1120.	1.3	38
527	Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2003, 284, L279-L289.	1.3	96
528	Glucocorticoids and Asthma. , 2003, , 127-134.		0
529	Update on asthma. <i>Israel Medical Association Journal</i> , 2003, 5, 68-72.	0.1	2
530	New treatments for chronic obstructive pulmonary disease. <i>Annali Dell'Istituto Superiore Di Sanita</i> , 2003, 39, 573-82.	0.2	6
531	A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 8921-8926.	3.3	461
532	Increased Exhaled Cysteinyl-Leukotrienes and 8-Isoprostane in Aspirin-induced Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002, 166, 301-306.	2.5	186
533	CYTOKINEMODULATORS AS NOVEL THERAPIES FOR ASTHMA. <i>Annual Review of Pharmacology and Toxicology</i> , 2002, 42, 81-98.	4.2	107
534	Comparison of the Effects of Salmeterol and Formoterol in Patients With Severe Asthma. <i>Chest</i> , 2002, 121, 1401-1406.	0.4	27
535	Increased 8-Isoprostane and Interleukin-6 in Breath Condensate of Obstructive Sleep Apnea Patients. <i>Chest</i> , 2002, 122, 1162-1167.	0.4	243
536	Alveolar macrophage-mediated elastolysis: roles of matrix metalloproteinases, cysteine, and serine proteases. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2002, 283, L867-L873.	1.3	208
537	Expression and Regulation of Inducible Nitric Oxide Synthase from Human Primary Airway Epithelial Cells. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2002, 26, 144-151.	1.4	78
538	Responses of Leukocytes to Chemokines in Whole Blood and Their Antagonism by Novel CC-Chemokine Receptor 3 Antagonists. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002, 165, 1602-1609.	2.5	52
539	Faster Rise of Exhaled Breath Temperature in Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002, 165, 181-184.	2.5	104
540	Release and Activity of Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 by Alveolar Macrophages from Patients with Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2002, 26, 602-609.	1.4	386

#	ARTICLE	IF	CITATIONS
541	Measurement of exhaled nitric oxide in children, 2001: E. Baraldi and J.C. de Jongste on behalf of the Task Force. <i>European Respiratory Journal</i> , 2002, 20, 223-237.	3.1	303
542	Increased Leukotrienes in Exhaled Breath Condensate in Childhood Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002, 166, 1345-1349.	2.5	190
543	Increased p21 ^{CIP1} /WAF1 and B Cell Lymphoma Leukemia-xL Expression and Reduced Apoptosis in Alveolar Macrophages from Smokers. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002, 166, 724-731.	2.5	121
544	Analysis of Expired Air for Oxidation Products. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002, 166, S31-S37.	2.5	160
545	The management of newly identified asthma in primary care in England. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2002, 11, 120-122.	2.5	10
546	Pathophysiology of Asthma. , 2002, , 343-359.		12
547	Effect of Theophylline on Induced Sputum Inflammatory Indices and Neutrophil Chemotaxis in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002, 165, 1371-1376.	2.5	163
548	Expression and Activity of Histone Deacetylases in Human Asthmatic Airways. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002, 166, 392-396.	2.5	296
549	Scientific rationale for inhaled combination therapy with long-acting β_2 -agonists and corticosteroids. <i>European Respiratory Journal</i> , 2002, 19, 182-191.	3.1	421
550	Increased expression of nuclear factor- κ B in bronchial biopsies from smokers and patients with COPD. <i>European Respiratory Journal</i> , 2002, 20, 556-563.	3.1	383
551	The trials and tribulations of anti-IL-5. <i>Journal of Allergy and Clinical Immunology</i> , 2002, 109, 575.	1.5	4
552	Exhaled leukotrienes and prostaglandins in asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2002, 109, 615-620.	1.5	210
553	p38 Mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: Role in steroid-insensitive asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2002, 109, 649-657.	1.5	378
554	Biomarkers of some pulmonary diseases in exhaled breath. <i>Biomarkers</i> , 2002, 7, 1-32.	0.9	254
555	Attenuated Production of Intracellular IL-10 and IL-12 in Monocytes from Patients with Severe Asthma. <i>Clinical Immunology</i> , 2002, 102, 258-266.	1.4	50
556	The role of inflammation and anti-inflammatory medication in asthma. <i>Respiratory Medicine</i> , 2002, 96, S9-S15.	1.3	20
557	Are mast cells still important in asthma?. <i>Revue Francaise D'allergologie Et D'immunologie Clinique</i> , 2002, 42, 20-27.	0.1	1
558	Analysis of exhaled breath condensate for monitoring airway inflammation. <i>Trends in Pharmacological Sciences</i> , 2002, 23, 232-237.	4.0	171

#	ARTICLE	IF	CITATIONS
559	Increased expression of G protein-coupled receptor kinases in cystic fibrosis lung. <i>European Journal of Pharmacology</i> , 2002, 436, 165-172.	1.7	42
560	New treatments for copd. <i>Nature Reviews Drug Discovery</i> , 2002, 1, 437-446.	21.5	131
561	Glucocorticoids reverse IL-1 β -induced impairment of β_2 -adrenoceptor-mediated relaxation and up-regulation of G-protein-coupled receptor kinases. <i>British Journal of Pharmacology</i> , 2002, 135, 987-996.	2.7	71
562	Effect of dopamine receptor agonists on sensory nerve activity: possible therapeutic targets for the treatment of asthma and COPD. <i>British Journal of Pharmacology</i> , 2002, 136, 620-628.	2.7	42
563	Tiotropium bromide: A novel once-daily anticholinergic bronchodilator for the treatment of COPD. <i>Drugs of Today</i> , 2002, 38, 585.	2.4	53
564	Future Therapies. , 2002, , 641-656.		0
565	Neural and Humoral Control. , 2002, , 323-340.		2
566	Future Therapies for Asthma. <i>Lung Biology in Health and Disease</i> , 2002, , 353-382.	0.1	0
567	Autonomic Control of the Airways. , 2002, , 432-454.		0
568	Current and future therapies for airway mucus hypersecretion. <i>Novartis Foundation Symposium</i> , 2002, 248, 237-49; discussion 249-53, 277-82.	1.2	5
569	Cytokine-directed therapies for asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2001, 108, S72-S76.	1.5	65
570	GM-CSF Expression in Pulmonary Epithelial Cells Is Regulated Negatively by Posttranscriptional Mechanisms. <i>Biochemical and Biophysical Research Communications</i> , 2001, 287, 249-253.	1.0	20
571	Th2 cytokines and asthma: an introduction. <i>Respiratory Research</i> , 2001, 2, 64.	1.4	174
572	Adding formoterol to budesonide in moderate asthma—health economic results from the FACET study. <i>Respiratory Medicine</i> , 2001, 95, 505-512.	1.3	46
573	Clinical outcome of adding long-acting β_2 -agonists to inhaled corticosteroids. <i>Respiratory Medicine</i> , 2001, 95, S12-S16.	1.3	18
574	Neurogenic inflammation in the airways. <i>Respiration Physiology</i> , 2001, 125, 145-154.	2.8	250
575	Eosinophils and airway hyper-responsiveness. <i>Lancet, The</i> , 2001, 357, 1446.	6.3	0
576	Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo-controlled trial. <i>Lancet, The</i> , 2001, 357, 2007-2011.	6.3	157

#	ARTICLE	IF	CITATIONS
577	Montelukast for persistent asthma. <i>Lancet</i> , The, 2001, 358, 1455-1456.	6.3	0
578	The Need for New Therapy. , 2001, 31, 2-5.		5
579	Clinical Studies on New Drugs. , 2001, 31, 48-51.		1
580	Current Therapy for Asthma. , 2001, 31, 6-10.		0
581	Cytokine modulators for allergic diseases. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2001, 1, 555-560.	1.1	25
582	Exhaled markers of inflammation. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2001, 1, 217-224.	1.1	73
583	Reduced Acetylation of Histone 4 in Corticosteroid-Resistant and Corticosteroid-Dependent Asthma. <i>Clinical Science</i> , 2001, 100, 12P-12P.	0.0	2
584	Expression of GATA family of transcription factors in T-cells, monocytes and bronchial biopsies. <i>European Respiratory Journal</i> , 2001, 18, 466-473.	3.1	72
585	Increased nitrotyrosine in exhaled breath condensate in cystic fibrosis. <i>European Respiratory Journal</i> , 2001, 17, 1201-1207.	3.1	102
586	Exhaled Carbon Monoxide and Nitric Oxide in COPD. <i>Chest</i> , 2001, 120, 496-501.	0.4	149
587	Novel drugs for treating asthma. <i>Current Allergy and Asthma Reports</i> , 2001, 1, 164-173.	2.4	27
588	TGF β 1 allele association with asthma severity. <i>Human Genetics</i> , 2001, 109, 623-627.	1.8	174
589	Chronic systemic administration of salmeterol to rats promotes pulmonary β 2-adrenoceptor desensitization and down-regulation of Gs α . <i>British Journal of Pharmacology</i> , 2001, 132, 1261-1270.	2.7	30
590	Evidence that the anti-spasmogenic effect of the β 2-adrenoceptor agonist, isoprenaline, on guinea-pig trachealis is not mediated by cyclic AMP-dependent protein kinase. <i>British Journal of Pharmacology</i> , 2001, 133, 1201-1212.	2.7	40
591	Effect of 8-iso-prostaglandin F $_{2\alpha}$ on acetylcholine release from parasympathetic nerves in guinea pig airways. <i>European Journal of Pharmacology</i> , 2001, 416, 231-234.	1.7	19
592	Release of nerve growth factor by human pulmonary epithelial cells: role in airway inflammatory diseases. <i>European Journal of Pharmacology</i> , 2001, 424, 159-162.	1.7	86
593	Glucocorticoid-mediated transrepression is regulated by histone acetylation and DNA methylation. <i>European Journal of Pharmacology</i> , 2001, 429, 327-334.	1.7	73
594	Molecular mechanisms of atopy. <i>Mediators of Inflammation</i> , 2001, 10, 285-288.	1.4	1

#	ARTICLE	IF	CITATIONS
595	p65-activated Histone Acetyltransferase Activity Is Repressed by Glucocorticoids. <i>Journal of Biological Chemistry</i> , 2001, 276, 30208-30215.	1.6	123
596	Does Exhaled Nitric Oxide Reflect Asthma Control?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2001, 164, 727-728.	2.5	46
597	Expression of Heme Oxygenase in Human Airway Epithelial Cells. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2001, 24, 295-303.	1.4	88
598	Tiotropium bromide. <i>Expert Opinion on Investigational Drugs</i> , 2001, 10, 733-740.	1.9	43
599	Corticosteroids, IgE, and atopy. <i>Journal of Clinical Investigation</i> , 2001, 107, 265-266.	3.9	56
600	Inflammatory Mediators and Neural Mechanisms in Severe Asthma. <i>Lung Biology in Health and Disease</i> , 2001, , 67-87.	0.1	0
601	Molecular Basis for Corticosteroid Action in Asthma. , 2000, 78, 72-80.		16
602	Clinical aspects of exhaled nitric oxide. <i>European Respiratory Journal</i> , 2000, 16, 781-792.	3.1	186
603	The Pharmacological Properties of Tiotropium. <i>Chest</i> , 2000, 117, 63S-66S.	0.4	185
604	Nasal and Exhaled Nitric Oxide Is Reduced in Adult Patients With Cystic Fibrosis and Does Not Correlate With Cystic Fibrosis Genotype. <i>Chest</i> , 2000, 117, 1085-1089.	0.4	105
605	The MAP kinase inhibitors, PD098059, UO126 and SB203580, inhibit IL-1 β -dependent PGE ₂ release via mechanistically distinct processes. <i>British Journal of Pharmacology</i> , 2000, 130, 1353-1361.	2.7	80
606	Extracellular signal-regulated kinase 1/2 control Ca ²⁺ -independent force development in histamine-stimulated bovine tracheal smooth muscle. <i>British Journal of Pharmacology</i> , 2000, 131, 981-989.	2.7	7
607	p38 MAP kinase and MKK-1 co-operate in the generation of GM-CSF from LPS-stimulated human monocytes by an NF- κ B-independent mechanism. <i>British Journal of Pharmacology</i> , 2000, 131, 1143-1153.	2.7	69
608	Transforming growth factor- β 1 inhibits β 2 -adrenoceptor gene transcription. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2000, 362, 520-525.	1.4	33
609	Pleiotropic role of lyn kinase in leukotriene B ₄ -induced eosinophil activation. <i>Blood</i> , 2000, 95, 3541-3547.	0.6	34
610	Mechanisms in COPD. <i>Chest</i> , 2000, 117, 10S-14S.	0.4	257
611	Molecular Regulation of Granulocyte Macrophage Colony-Stimulating Factor in Human Lung Epithelial Cells by Interleukin (IL)-1 β , IL-4, and IL-13 Involves Both Transcriptional and Post-Transcriptional Mechanisms. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2000, 22, 582-589.	1.4	54
612	Novel therapy for asthma. <i>Expert Opinion on Investigational Drugs</i> , 2000, 9, 25-42.	1.9	20

#	ARTICLE	IF	CITATIONS
613	Glucocorticoid Receptor Recruitment of Histone Deacetylase 2 Inhibits Interleukin-1 β -Induced Histone H4 Acetylation on Lysines 8 and 12. <i>Molecular and Cellular Biology</i> , 2000, 20, 6891-6903.	1.1	677
614	Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. <i>Lancet</i> , The, 2000, 356, 2144-2148.	6.3	1,700
615	Stimulus-Specific Inhibition of IL-5 by cAMP-Elevating Agents and IL-10 Reveals Differential Mechanisms of Action. <i>Biochemical and Biophysical Research Communications</i> , 2000, 273, 811-815.	1.0	37
616	Ceramide Induction of COX-2 and PGE2 in Pulmonary A549 Cells Does Not Involve Activation of NF- κ B. <i>Biochemical and Biophysical Research Communications</i> , 2000, 277, 675-679.	1.0	34
617	New treatments for asthma. <i>European Journal of Internal Medicine</i> , 2000, 11, 9-20.	1.0	12
618	Regular inhaled salbutamol and asthma control: the TRUST randomised trial. <i>Lancet</i> , The, 2000, 355, 1675-1679.	6.3	100
619	Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response. <i>Lancet</i> , The, 2000, 356, 2149-2153.	6.3	380
620	Chronic Obstructive Pulmonary Disease. <i>New England Journal of Medicine</i> , 2000, 343, 269-280.	13.9	1,189
621	Anti-IgE Therapy in Asthma: Rationale and Therapeutic Potential. <i>International Archives of Allergy and Immunology</i> , 2000, 123, 196-204.	0.9	42
622	Novel therapy for COPD. <i>Expert Opinion on Investigational Drugs</i> , 2000, 9, 3-23.	1.9	15
623	Delayed eosinophil apoptosis in asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2000, 106, 77-83.	1.5	163
624	New directions in allergic diseases: Mechanism-based anti-inflammatory therapies. <i>Journal of Allergy and Clinical Immunology</i> , 2000, 106, 5-16.	1.5	93
625	Neuropeptides and Asthma. <i>Allergy and Clinical Immunology International</i> , 2000, 12, 0054-0059.	0.3	2
626	Nitric Oxide in Exhaled Air: Relevance in Inflammatory Lung Disease. , 2000, , 167-183.		0
627	The Pathogenesis and Treatment of Asthma as an Inflammatory Disease. , 2000, , 221-236.		0
628	1 β -Adrenoceptor Agonist-Induced Upregulation of Tachykinin NK2Receptor Expression and Function in Airway Smooth Muscle. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 1999, 21, 409-417.	1.4	27
629	Anti-IgE Antibody Therapy for Asthma. <i>New England Journal of Medicine</i> , 1999, 341, 2006-2008.	13.9	30
630	Differential κ B Kinase Activation and κ B β Degradation by Interleukin-1 β and Tumor Necrosis Factor- α in Human U937 Monocytic Cells. <i>Journal of Biological Chemistry</i> , 1999, 274, 19965-19972.	1.6	154

#	ARTICLE	IF	CITATIONS
631	Therapeutic strategies for allergic diseases. <i>Nature</i> , 1999, 402, 31-38.	13.7	204
632	Pharmacological characterization of the muscarinic receptor antagonist, glycopyrrolate, in human and guinea-pig airways. <i>British Journal of Pharmacology</i> , 1999, 127, 413-420.	2.7	72
633	Ligand-induced differentiation of glucocorticoid receptor (GR) trans-repression and transactivation: preferential targetting of NF- κ B and lack of I- κ B involvement. <i>British Journal of Pharmacology</i> , 1999, 127, 1003-1011.	2.7	106
634	Involvement of cysteinyl leukotrienes in airway smooth muscle cell DNA synthesis after repeated allergen exposure in sensitized Brown Norway rats. <i>British Journal of Pharmacology</i> , 1999, 127, 1151-1158.	2.7	71
635	Sputum Induction as a Method of Analyzing Pulmonary Cells: Reproducibility and Acceptability. <i>Journal of Asthma</i> , 1999, 36, 335-341.	0.9	10
636	Exhaled carbon monoxide in childhood asthma. <i>Journal of Pediatrics</i> , 1999, 135, 569-574.	0.9	88
637	Salmeterol/Fluticasone Propionate Combination. <i>Drugs</i> , 1999, 57, 941-943.	4.9	0
638	Effect of β_2 agonists on inflammatory cells. <i>Journal of Allergy and Clinical Immunology</i> , 1999, 104, S10-S17.	1.5	123
639	Changes in exhaled carbon monoxide and nitric oxide levels following allergen challenge in patients with asthma. <i>European Respiratory Journal</i> , 1999, 13, 48-52.	3.1	90
640	Prostaglandins mediate bradykinin-induced reduction of exhaled nitric oxide in asthma. <i>European Respiratory Journal</i> , 1999, 14, 1023-1027.	3.1	18
641	Exhaled Nitric Oxide Is Increased in Active Fibrosing Alveolitis. <i>Chest</i> , 1999, 115, 1352-1356.	0.4	97
642	Transcription Factors and Inflammatory Lung Disease. , 1999, , 41-70.		1
643	New Targets for Future Asthma Therapy. , 1999, , 361-389.		0
644	Prostaglandin E2 suppression of acetylcholine release from parasympathetic nerves innervating guinea-pig trachea by interacting with prostanoid receptors of the EP3 -subtype. <i>British Journal of Pharmacology</i> , 1998, 123, 1246-1252.	2.7	32
645	Inhibitory cytokines in asthma. <i>Trends in Molecular Medicine</i> , 1998, 4, 452-458.	2.6	43
646	Effect of dexamethasone on interleukin-1 β -induced nuclear factor-kappaB (NF-kappaB) and kappaB-dependent transcription in epithelial cells. <i>FEBS Journal</i> , 1998, 254, 81-89.	0.2	93
647	Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumor necrosis factor- α generation from human peripheral blood monocytes. <i>Cell Biochemistry and Biophysics</i> , 1998, 29, 179-201.	0.9	53
648	Muscarinic receptor subtypes in airways. <i>Research in Immunology</i> , 1998, 149, 201-202.	0.9	1

#	ARTICLE	IF	CITATIONS
649	The mode of action of corticosteroids in asthma. <i>Research in Immunology</i> , 1998, 149, 225-226.	0.9	5
650	Current issues for establishing inhaled corticosteroids as the antiinflammatory agents of choice in asthma. <i>Journal of Allergy and Clinical Immunology</i> , 1998, 101, S427-S433.	1.5	76
651	Glucocorticoids reduce tachykinin NK2 receptor expression in bovine tracheal smooth muscle. <i>European Journal of Pharmacology</i> , 1998, 344, 99-106.	1.7	31
652	Induction of Phosphodiesterases 3B, 4A4, 4D1, 4D2, and 4D3 in Jurkat T-cells and in Human Peripheral Blood T-lymphocytes by 8-Bromo-cAMP and Gs-coupled Receptor Agonists. <i>Journal of Biological Chemistry</i> , 1998, 273, 20575-20588.	1.6	97
653	Pathophysiology of Asthma. , 1998, , 487-506.		0
654	Repression of Cyclooxygenase-2 and Prostaglandin E2Release by Dexamethasone Occurs by Transcriptional and Post-transcriptional Mechanisms Involving Loss of Polyadenylated mRNA. <i>Journal of Biological Chemistry</i> , 1998, 273, 32312-32321.	1.6	168
655	Î² ₂ Degradation and Nuclear Factor-Î² DNA Binding Are Insufficient for Interleukin-1 ^{Î²} and Tumor Necrosis Factor-Î±-induced Î²-dependent Transcription. <i>Journal of Biological Chemistry</i> , 1998, 273, 6607-6610.	1.6	179
656	Mediator Antagonists. , 1998, , 767-782.		0
657	Recommendations based on guidelines on the management of mild to moderately severe chronic obstructive pulmonary disease: some practical applications in primary care. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 1998, 6, 35-39.	2.5	0
658	Anti-inflammatory Actions of Glucocorticoids: Molecular Mechanisms. <i>Clinical Science</i> , 1998, 94, 557-572.	1.8	1,268
659	Effect of inhaled corticosteroids on bones and growth. <i>European Respiratory Journal</i> , 1998, 11, 1167-1177.	3.1	63
660	Transcription factors and asthma. <i>European Respiratory Journal</i> , 1998, 12, 221-234.	3.1	267
661	Effect of nitric oxide synthesis inhibition with nebulized L-NAME on ventilation-perfusion distributions in bronchial asthma. <i>European Respiratory Journal</i> , 1998, 12, 865-871.	3.1	12
662	An inhaled steroid improves markers of airway inflammation in patients with mild asthma. <i>European Respiratory Journal</i> , 1998, 12, 1084-1088.	3.1	87
663	Difficult asthma. <i>European Respiratory Journal</i> , 1998, 12, 1209-1218.	3.1	225
664	Increased formation of the potent oxidant peroxynitrite in the airways of asthmatic patients is associated with induction of nitric oxide synthase: effect of inhaled glucocorticoid. <i>FASEB Journal</i> , 1998, 12, 929-937.	0.2	398
665	NANC Nerves and Neuropeptides. , 1998, , 423-457.		2
666	Transcription Factors. , 1998, , 459-474.		4

#	ARTICLE	IF	CITATIONS
667	Glucocorticosteroids. , 1998, , 725-766.		4
668	Zafirlukast (Accolate). Drugs of Today, 1998, 34, 375.	0.7	6
669	Transcription Factors in Asthma. , 1998, , 25-45.		3
670	Future Therapies for Asthma. , 1998, , 795-819.		0
671	Neural mechanisms in asthma: New developments. Pediatric Pulmonology, 1997, 23, 82-83.	1.0	3
672	Effect of Inhaled Formoterol and Budesonide on Exacerbations of Asthma. New England Journal of Medicine, 1997, 337, 1405-1411.	13.9	1,478
673	A Comparison of Low-Dose Inhaled Budesonide plus Theophylline and High-Dose Inhaled Budesonide for Moderate Asthma. New England Journal of Medicine, 1997, 337, 1412-1419.	13.9	355
674	Effect of short- and long-acting inhaled β_2 -agonists on exhaled nitric oxide in asthmatic patients. European Respiratory Journal, 1997, 10, 1483-1488.	3.1	85
675	Protein kinase C isoenzymes in airway smooth muscle. Biochemical Journal, 1997, 324, 167-175.	1.7	28
676	Current Therapies for Asthma. Chest, 1997, 111, 17S-26S.	0.4	61
677	Exhaled and nasal nitric oxide measurements: recommendations. European Respiratory Journal, 1997, 10, 1683-1693.	3.1	595
678	Effect of 5-HTA receptor agonist, 8-OH-DPAT, on cough responses in the conscious guinea-pig. European Journal of Pharmacology, 1997, 332, 201-207.	1.7	18
679	Nasal nitric oxide is increased in patients with asthma and allergic rhinitis and may be modulated by nasal glucocorticoids. Journal of Allergy and Clinical Immunology, 1997, 99, 58-64.	1.5	100
680	Alternate COX-2 Transcripts Are Differentially Regulated: Implications for Post-Transcriptional Control. Biochemical and Biophysical Research Communications, 1997, 234, 85-89.	1.0	55
681	Evidence for Involvement of NF- κ B in the Transcriptional Control of COX-2 Gene Expression by IL-1 β . Biochemical and Biophysical Research Communications, 1997, 237, 28-32.	1.0	382
682	Nuclear factor- κ B. International Journal of Biochemistry and Cell Biology, 1997, 29, 867-870.	1.2	328
683	Superinduction of COX-2 mRNA by cycloheximide and interleukin-1 β involves increased transcription and correlates with increased NF- κ B and JNK activation. FEBS Letters, 1997, 418, 135-138.	1.3	102
684	Nuclear Factor- κ B "A Pivotal Transcription Factor in Chronic Inflammatory Diseases. New England Journal of Medicine, 1997, 336, 1066-1071.	13.9	4,447

#	ARTICLE	IF	CITATIONS
685	NF- κ B: a pivotal role in asthma and a new target for therapy. <i>Trends in Pharmacological Sciences</i> , 1997, 18, 46-50.	4.0	198
686	Inducible nitric oxide synthase after sensitization and allergen challenge of Brown Norway rat lung. <i>British Journal of Pharmacology</i> , 1997, 121, 1241-1246.	2.7	55
687	Characterization of the prostanoid receptor(s) on human blood monocytes at which prostaglandin E2 inhibits lipopolysaccharide-induced tumour necrosis factor- α generation. <i>British Journal of Pharmacology</i> , 1997, 122, 149-157.	2.7	90
688	Pathophysiology and clinical presentations of cough. <i>Journal of Allergy and Clinical Immunology</i> , 1996, 98, S91-S97.	1.5	66
689	Cyclic AMP-elevating agents prolong or inhibit eosinophil survival depending on prior exposure to GM-CSF. <i>British Journal of Pharmacology</i> , 1996, 117, 79-86.	2.7	39
690	Involvement of hydroxyl radicals in neurogenic airway plasma exudation and bronchoconstriction in guinea-pigs <i>in vivo</i> . <i>British Journal of Pharmacology</i> , 1996, 117, 449-454.	2.7	22
691	Nitric oxide inhibition of basal and neurogenic mucus secretion in ferret trachea <i>in vitro</i> . <i>British Journal of Pharmacology</i> , 1996, 118, 998-1002.	2.7	33
692	Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4 ⁺ and CD8 ⁺ T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2. <i>British Journal of Pharmacology</i> , 1996, 118, 1945-1958.	2.7	196
693	Ozone induction of cytokine-induced neutrophil chemoattractant (CINC) and nuclear factor- κ B in rat lung: inhibition by corticosteroids. <i>FEBS Letters</i> , 1996, 379, 265-268.	1.3	94
694	Superinduction of NF- κ B by Actinomycin D and Cycloheximide in Epithelial Cells. <i>Biochemical and Biophysical Research Communications</i> , 1996, 218, 518-523.	1.0	76
695	Tumour Necrosis Factor- α Causes Retention of Activated Glucocorticoid Receptor within the Cytoplasm of A549 Cells. <i>Biochemical and Biophysical Research Communications</i> , 1996, 225, 545-550.	1.0	31
696	Cytokine induction of cytosolic phospholipase A2 and cyclooxygenase-2 mRNA is suppressed by glucocorticoids in human epithelial cells. <i>Life Sciences</i> , 1996, 60, 67-78.	2.0	139
697	Inhaled glucocorticoids: new developments relevant to updating of the Asthma Management Guidelines. <i>Respiratory Medicine</i> , 1996, 90, 379-384.	1.3	34
698	Exhaled nitric oxide. <i>Current Opinion in Anaesthesiology</i> , 1996, 9, 542-548.	0.9	13
699	Interactions of glucocorticoids and β_2 -agonists. <i>European Respiratory Journal</i> , 1996, 9, 160-168.	3.1	68
700	Changes in the dose of inhaled steroid affect exhaled nitric oxide levels in asthmatic patients. <i>European Respiratory Journal</i> , 1996, 9, 196-201.	3.1	214
701	The costs of asthma. <i>European Respiratory Journal</i> , 1996, 9, 636-642.	3.1	376
702	Priming of circulating human eosinophils following late response to allergen challenge. <i>European Respiratory Journal</i> , 1996, 9, 703-708.	3.1	29

#	ARTICLE	IF	CITATIONS
703	The effect of alcohol ingestion on exhaled nitric oxide. <i>European Respiratory Journal</i> , 1996, 9, 1130-1133.	3.1	50
704	Phosphodiesterase 4 in macrophages: relationship between cAMP accumulation, suppression of cAMP hydrolysis and inhibition of [³ H]R-(α)-rolipram binding by selective inhibitors. <i>Biochemical Journal</i> , 1996, 318, 425-436.	1.7	42
705	LIGAND-INDUCED DIFFERENTIATION OF GLUCOCORTICOID RECEPTOR (GR) TRANS-REPRESSION AND TRANSACTIVATION. <i>Biochemical Society Transactions</i> , 1996, 24, 267S-267S.	1.6	16
706	CYTOKINE mRNA PROFILES OF NORMAL AND ASTHMATIC PERIPHERAL BLOOD CELLS AND ENDOBRONCHIAL BIOPSIES. <i>Biochemical Society Transactions</i> , 1996, 24, 315S-315S.	1.6	3
707	T CELL RECEPTOR REPERTOIRE IN PERIPHERAL BLOOD AND BRONCHIAL BIOPSIES FROM NORMAL AND ASTHMATIC SUBJECTS. <i>Biochemical Society Transactions</i> , 1996, 24, 316S-316S.	1.6	2
708	Differential Regulation of Cyclo-Oxygenase-1 and Cyclo-Oxygenase-2 Gene Expression by Lipopolysaccharide Treatment in vivo in the Rat. <i>Clinical Science</i> , 1996, 90, 301-306.	1.8	99
709	Autoradiographic mapping of beta-adrenoceptors in human skin. <i>Archives of Dermatological Research</i> , 1996, 288, 549-553.	1.1	58
710	Pathophysiology of asthma. <i>British Journal of Clinical Pharmacology</i> , 1996, 42, 3-10.	1.1	193
711	Bradykinin-evoked sensitization of airway sensory nerves: A mechanism for ACE-inhibitor cough. <i>Nature Medicine</i> , 1996, 2, 814-817.	15.2	270
712	Asthma Therapy with Aerosols: Clinical Relevance for the Next Decade. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 1996, 9, 131-141.	1.2	3
713	9. Why Does Asthma Become Persistent?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1996, 153, S23-S25.	2.5	3
714	2. What Is the Role of Nerves in Chronic Asthma and Symptoms?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1996, 153, S5-S8.	2.5	14
715	Mechanisms of Action of Glucocorticoids in Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1996, 154, S21-S27.	2.5	127
716	Is Immunotherapy for Asthma Worthwhile?. <i>New England Journal of Medicine</i> , 1996, 334, 531-532.	13.9	60
717	Autoradiographic mapping of beta-adrenoceptors in human skin. <i>Archives of Dermatological Research</i> , 1996, 288, 549-553.	1.1	9
718	Use of a Fixed Combination β_2 -Agonist and Steroid Dry Powder Inhaler in Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1995, 151, 1053-1057.	2.5	0
719	l-Arginine Increases Exhaled Nitric Oxide in Normal Human Subjects. <i>Clinical Science</i> , 1995, 88, 135-139.	1.8	152
720	From pathophysiological mechanisms to pharmacological treatment of childhood asthma. <i>Pediatric Pulmonology</i> , 1995, 19, 40-41.	1.0	1

#	ARTICLE	IF	CITATIONS
721	Nitric oxide and asthmatic inflammation. Trends in Immunology, 1995, 16, 128-130.	7.5	478
722	Î² ₂ -adrenoceptor agonists interfere with glucocorticoid receptor DNA binding in rat lung. European Journal of Pharmacology, 1995, 289, 275-281.	2.7	69
723	Nitric Oxide and Airway Disease. Annals of Medicine, 1995, 27, 389-393.	1.5	246
724	Transcriptional Down-regulation of m2 Muscarinic Receptor Gene Expression in Human Embryonic Lung (HEL 299) Cells by Protein Kinase C. Journal of Biological Chemistry, 1995, 270, 7213-7218.	1.6	39
725	Is Asthma a Nervous Disease?. Chest, 1995, 107, 119S-125S.	0.4	49
726	Glucocorticoid Resistance in Asthma. American Journal of Respiratory and Critical Care Medicine, 1995, 152, S125-S140.	2.5	146
727	Nitric oxide and asthma. Research in Immunology, 1995, 146, 698-702.	0.9	28
728	Nitric oxide synthase activity is elevated in inflammatory lung disease in humans. European Journal of Pharmacology, 1995, 283, 255-258.	1.7	67
729	Inhaled Glucocorticoids for Asthma. New England Journal of Medicine, 1995, 332, 868-875.	13.9	605
730	Molecular Mechanisms of Antiasthma Therapy. Annals of Medicine, 1995, 27, 531-535.	1.5	27
731	Tiotropium bromide (Ba 679 BR), a novel long-acting muscarinic antagonist for the treatment of obstructive airways disease. Life Sciences, 1995, 56, 853-859.	2.0	109
732	Dexamethasone inhibits ozone-induced gene expression of macrophage inflammatory protein-2 in rat lung. FEBS Letters, 1995, 363, 285-288.	1.3	27
733	Effects of capsazepine against capsaicin- and proton-evoked excitation of single airway C-fibres and vagus nerve from the guinea-pig. Neuroscience, 1995, 67, 741-752.	1.1	112
734	Molecular Mechanisms of Anti-Asthma Therapy. , 1995, , 403-409.		2
735	Cytokines as Mediators of Chronic Asthma. American Journal of Respiratory and Critical Care Medicine, 1994, 150, S42-S49.	2.5	163
736	High affinity [3H]formoterol binding sites in lung: characterization and autoradiographic mapping. European Journal of Pharmacology, 1994, 269, 35-41.	2.7	28
737	Effect of interleukin-1Î² on airway hyperresponsiveness and inflammation in sensitized and nonsensitized Brown-Norway rats. Journal of Allergy and Clinical Immunology, 1994, 93, 464-469.	1.5	58
738	Oxidative Stress Induces NFÎ±B DNA Binding and Inducible NOS mRNA in Human Epithelial Cells. Biochemical and Biophysical Research Communications, 1994, 199, 1518-1524.	1.0	257

#	ARTICLE	IF	CITATIONS
739	Barnes and Adcock reply. Trends in Pharmacological Sciences, 1994, 15, 139.	4.0	1
740	Increased nitric oxide in exhaled air of asthmatic patients. Lancet, The, 1994, 343, 133-135.	6.3	1,373
741	Inhibition of excitatory nonadrenergic noncholinergic bronchoconstriction in guinea pig airways <i>in vitro</i> by activation of an atypical 5-HT receptor. British Journal of Pharmacology, 1994, 111, 1095-1102.	2.7	16
742	Induction of cyclooxygenase-2 by cytokines in human pulmonary epithelial cells: regulation by dexamethasone. British Journal of Pharmacology, 1994, 113, 1008-1014.	2.7	278
743	The effects of glucocorticoids on phorbol ester and cytokine stimulated transcription factor activation in human lung. Life Sciences, 1994, 55, 1147-1153.	2.0	77
744	Modulation of airway smooth muscle β_2 -adrenoceptor function by a muscarinic agonist. Life Sciences, 1994, 54, 185-191.	2.0	47
745	Nitric oxide in lung disorders. Biomedicine and Pharmacotherapy, 1994, 48, 409.	2.5	0
746	Blunted Perception and Death from Asthma. New England Journal of Medicine, 1994, 330, 1383-1384.	13.9	84
747	Role of Endothelium in the Control of Pulmonary Vascular Tone. Endothelium: Journal of Endothelial Cell Research, 1994, 2, 11-33.	1.7	11
748	Oxidative stress induces NF κ B DNA binding and inducible NOS mRNA in the human epithelial cell line A549. Biochemical Society Transactions, 1994, 22, 186S-186S.	1.6	13
749	Endotoxin and steroid effects on nitric oxide synthase mRNA expression in rat lung and other tissues. Biochemical Society Transactions, 1994, 22, 188S-188S.	1.6	5
750	Dexamethasone action on <i>c-fos</i> and <i>c-jun</i> mRNA and protein in human lung. Biochemical Society Transactions, 1994, 22, 187S-187S.	1.6	0
751	Contribution of Intercellular-Adhesion Molecule-1 in Allergen-Induced Airway Hyperresponsiveness and Inflammation in Sensitised Brown-Norway Rats. International Archives of Allergy and Immunology, 1994, 104, 291-295.	0.9	39
752	Effects of dexamethasone on cytokine and phorbol ester stimulated c-Fos and c-Jun DNA binding and gene expression in human lung. European Respiratory Journal, 1994, 7, 2117-2123.	3.1	46
753	Theophylline in the management of asthma: time for reappraisal?. European Respiratory Journal, 1994, 7, 579-591.	3.1	235
754	Modulation of Neurotransmitter Release from Airways Nerves. , 1994, , 209-259.		8
755	Effect of CP-96,345, a non-peptide NK1 receptor antagonist, against substance P-, bradykinin- and allergen-induced airway microvascular leakage and bronchoconstriction in the guinea pig. European Journal of Pharmacology, 1993, 231, 31-38.	1.7	63
756	Platelet-activating factor-induced enhancement of superoxide anion generation in guinea-pigs. European Journal of Pharmacology, 1993, 232, 7-12.	1.7	28

#	ARTICLE	IF	CITATIONS
757	Lipopolysaccharide Treatment in Vivo Induces Widespread Tissue Expression of Inducible Nitric Oxide Synthase mRNA. <i>Biochemical and Biophysical Research Communications</i> , 1993, 196, 1208-1213.	1.0	260
758	Muscarinic receptor subtypes in airways. <i>Life Sciences</i> , 1993, 52, 521-527.	2.0	211
759	Effect of an inhaled histamine H3 receptor agonist on airway responses to sodium metabisulphite in asthma. <i>British Journal of Clinical Pharmacology</i> , 1993, 35, 55-57.	1.1	17
760	Effects of two novel tachykinin antagonists, FK224 and FK888, on neurogenic airway plasma exudation, bronchoconstriction and systemic hypotension in guinea pigs <i>in vivo</i> . <i>British Journal of Pharmacology</i> , 1993, 108, 844-851.	2.7	54
761	Attenuation of tachykinin-induced airflow obstruction and microvascular leakage in immature airways. <i>British Journal of Pharmacology</i> , 1993, 108, 23-29.	2.7	23
762	Regulation of NANC neural bronchoconstriction <i>in vivo</i> in the guinea pig: involvement of nitric oxide, vasoactive intestinal peptide and soluble guanylyl cyclase. <i>British Journal of Pharmacology</i> , 1993, 108, 228-235.	2.7	46
763	Endogenous tachykinins facilitate transmission through parasympathetic ganglia in guinea pig trachea. <i>British Journal of Pharmacology</i> , 1993, 109, 751-759.	2.7	56
764	Anti-inflammatory actions of steroids: molecular mechanisms. <i>Trends in Pharmacological Sciences</i> , 1993, 14, 436-441.	4.0	687
765	Efficacy and Safety of Inhaled Corticosteroids in Asthma. <i>The American Review of Respiratory Disease</i> , 1993, 148, S1-S26.	2.9	416
766	Role of nitric oxide and guanosine 3',5'-cyclic monophosphate in mediating nonadrenergic, noncholinergic relaxation in guinea pig pulmonary arteries. <i>British Journal of Pharmacology</i> , 1992, 107, 861-866.	2.7	53
767	Role of Potassium Channels in Bronchodilator Responses in Human Airways. <i>The American Review of Respiratory Disease</i> , 1992, 146, 132-136.	2.9	137
768	Greater Effect of Inhaled Budesonide on Adenosine 5'-Monophosphate-induced than on Sodium-Metabisulfite-induced Bronchoconstriction in Asthma. <i>The American Review of Respiratory Disease</i> , 1992, 146, 560-564.	2.9	108
769	A Comparison of β_2 -Adrenergic Receptors and <i>In Vitro</i> Relaxant Responses to Isoproterenol in Asthmatic Airway Smooth Muscle. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 1992, 6, 647-651.	1.4	102
770	Localization of Muscarinic Receptor Subtype mRNAs in Human Lung. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 1992, 7, 344-348.	1.4	125
771	Quantifying Proliferation of Cultured Human and Rabbit Airway Smooth Muscle Cells in Response to Serum and Platelet-derived Growth Factor. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 1992, 7, 574-581.	1.4	131
772	Effect of Dexamethasone and Cyclosporin A on Allergen-induced Airway Hyperresponsiveness and Inflammatory Cell Responses in Sensitized Brown-Norway Rats. <i>The American Review of Respiratory Disease</i> , 1992, 145, 1289-1294.	2.9	131
773	Neurogenic Inflammation and Asthma. <i>Journal of Asthma</i> , 1992, 29, 165-180.	0.9	78
774	ASTHMA THERAPY ??? PRESENT ANXIETIES AND FUTURE RESEARCH. <i>Adverse Drug Reaction Bulletin</i> , 1992, 154, 579-582.	0.6	1

#	ARTICLE	IF	CITATIONS
775	Tolerance to the Nonbronchodilator Effects of Inhaled β_2 -Agonists in Asthma. <i>New England Journal of Medicine</i> , 1992, 327, 1204-1208.	13.9	356
776	Pharmacological modulation of inhaled sodium metabisulphite-induced airway microvascular leakage and bronchoconstriction in the guinea pig. <i>British Journal of Pharmacology</i> , 1992, 107, 481-487.	2.7	21
777	Actions of methoctramine, a muscarinic M_2 receptor antagonist, on muscarinic and nicotinic cholinergic receptors in guinea pig airways <i>in vivo</i> and <i>in vitro</i> . <i>British Journal of Pharmacology</i> , 1992, 105, 107-112.	2.7	51
778	Inhibition of neurogenic plasma exudation in guinea pig airways by CP 96,345, a new non-peptide NK ₁ receptor antagonist. <i>British Journal of Pharmacology</i> , 1992, 105, 261-262.	2.7	97
779	Developmental changes in endothelium-dependent pulmonary vasodilatation in pigs. <i>British Journal of Pharmacology</i> , 1992, 106, 324-330.	2.7	97
780	Involvement of inflammatory mediators in the airway responses to trimellitic anhydride in sensitized guinea pigs. <i>British Journal of Pharmacology</i> , 1992, 106, 828-832.	2.7	23
781	Effect of frusemide on the induction and potentiation of cough induced by prostaglandin F ₂ alpha.. <i>British Journal of Clinical Pharmacology</i> , 1992, 33, 514-516.	1.1	9
782	The low-chloride cough response is not inhibited by a single, high dose of aspirin.. <i>British Journal of Clinical Pharmacology</i> , 1992, 34, 370-372.	1.1	3
783	Questions about inhaled β_2 -adrenoceptor agonists in asthma. <i>Trends in Pharmacological Sciences</i> , 1992, 13, 20-23.	4.0	75
784	Activation of guinea pig eosinophil respiratory burst by leukotriene B ₄ : role of protein kinase C. <i>Fundamental and Clinical Pharmacology</i> , 1992, 6, 353-358.	1.0	4
785	Effect of maturation on histamine-induced airflow obstruction and airway microvascular leakage in guinea pig airways. <i>European Journal of Pharmacology</i> , 1992, 215, 51-56.	1.7	21
786	Nitric oxide is the endogenous neurotransmitter of bronchodilator nerves in humans. <i>European Journal of Pharmacology</i> , 1992, 210, 221-222.	1.7	352
787	The effect of endogenous nitric oxide on neurogenic plasma exudation in guinea-pig airways. <i>European Journal of Pharmacology</i> , 1992, 221, 385-388.	1.7	112
788	Inhibition of eosinophil cyclic nucleotide PDE activity and opsonised zymosan-stimulated respiratory burst by V -type Ca^{2+} -selective PDE inhibitors. <i>British Journal of Pharmacology</i> , 1991, 103, 1339-1346.	2.7	131
789	Lack of effect of zaprinast on methacholine-induced contraction and inositol 1,4,5-trisphosphate accumulation in bovine tracheal smooth muscle. <i>British Journal of Pharmacology</i> , 1991, 103, 1119-1125.	2.7	27
790	Endogenous nitric oxide modulates adrenergic neural vasoconstriction in guinea pig pulmonary artery. <i>British Journal of Pharmacology</i> , 1991, 104, 565-569.	2.7	51
791	Differential effects of phosphoramidon on neurokinin A- and substance P-induced airflow obstruction and airway microvascular leakage in guinea pig. <i>British Journal of Pharmacology</i> , 1991, 104, 945-949.	2.7	11
792	Circulating autoantibodies to recombinant lipocortin-1 in asthma. <i>Respiratory Medicine</i> , 1991, 85, 121-124.	1.3	15

#	ARTICLE	IF	CITATIONS
793	Preventative therapy in adults with asthma. <i>Respiratory Medicine</i> , 1991, 85, 355-357.	1.3	2
794	Selective inhibition of a high affinity type IV cyclic AMP phosphodiesterase in bovine trachealis by AH 21-132. <i>Biochemical Pharmacology</i> , 1991, 42, 663-677.	2.0	36
795	Effect of tachykinins in small human airways. <i>Neuropeptides</i> , 1991, 19, 157-161.	0.9	47
796	Localization of beta pre-protachykinin mRNA in nodose ganglion. <i>Neuropeptides</i> , 1991, 20, 145-150.	0.9	5
797	Biochemistry of asthma. <i>Trends in Biochemical Sciences</i> , 1991, 16, 365-369.	3.7	45
798	Corticosteroid Inhibition of Airway Microvascular Leakage. <i>The American Review of Respiratory Disease</i> , 1991, 143, 605-609.	2.9	90
799	Neuropeptides in the Respiratory Tract: Part II. <i>The American Review of Respiratory Disease</i> , 1991, 144, 1391-1399.	2.9	206
800	Localization of β^2 -adrenoceptor messenger RNA in human and rat lung using in situ hybridization: correlation with receptor autoradiography. <i>European Journal of Pharmacology</i> , 1991, 206, 133-138.	2.7	69
801	Future drug therapy for asthma. <i>Clinical and Experimental Allergy</i> , 1991, 21, 80-85.	1.4	13
802	Neuropeptides in the Respiratory Tract: Part I. <i>The American Review of Respiratory Disease</i> , 1991, 144, 1187-1198.	2.9	424
803	Neuropeptides and Asthma. <i>The American Review of Respiratory Disease</i> , 1991, 143, S28-S32.	2.9	94
804	Endothelium-derived Relaxing Factor Inhibits Hypoxic Pulmonary Vasoconstriction in Rats. <i>The American Review of Respiratory Disease</i> , 1991, 143, 32-37.	2.9	183
805	Loop Diuretics Inhibit Cholinergic and Noncholinergic Nerves in Guinea Pig Airways. <i>The American Review of Respiratory Disease</i> , 1991, 143, 1340-1344.	2.9	80
806	Reactive oxygen species and airway inflammation. <i>Free Radical Biology and Medicine</i> , 1990, 9, 235-243.	1.3	460
807	The role of neurotransmitters in bronchial asthma. <i>Lung</i> , 1990, 168, 57-65.	1.4	3
808	The Action of a Potassium Channel Activator, BRL 38227 (Lemakalim), on Human Airway Smooth Muscle. <i>The American Review of Respiratory Disease</i> , 1990, 142, 1384-1389.	2.9	85
809	Effect of Inhaled Furosemide on Metabisulfite- and Methacholine-induced Bronchoconstriction and Nasal Potential Difference in Asthmatic Subjects. <i>The American Review of Respiratory Disease</i> , 1990, 142, 576-580.	2.9	118
810	Inhaled Furosemide Inhibits Cough Induced by Low Chloride Content Solutions but Not by Capsaicin. <i>The American Review of Respiratory Disease</i> , 1990, 142, 143-146.	2.9	123

#	ARTICLE	IF	CITATIONS
811	Chairman's Summary. The American Review of Respiratory Disease, 1990, 141, S97-S98.	2.9	55
812	Autoradiographic Visualization of Muscarinic Receptor Subtypes in Human and Guinea Pig Lung. The American Review of Respiratory Disease, 1990, 141, 1559-1568.	2.9	230
813	The Effects of Activated Eosinophils and Neutrophils on Guinea Pig Airway Epithelium In Vitro. American Journal of Respiratory Cell and Molecular Biology, 1990, 2, 341-353.	1.4	80
814	Modulation of neurogenic inflammation: novel approaches to inflammatory disease. Trends in Pharmacological Sciences, 1990, 11, 185-189.	4.0	187
815	Neuropeptides and asthma. European Journal of Pharmacology, 1990, 183, 94.	1.7	0
816	Biochemical and pharmacological interactions between the papaverine derivative, AH 21132, and methacholine in bovine tracheal smooth muscle. European Journal of Pharmacology, 1990, 183, 2157-2158.	1.7	5
817	Effects of aerosolised substance P on lung resistance in guinea pigs: a comparison between inhibition of neutral endopeptidase and angiotensin converting enzyme. British Journal of Pharmacology, 1990, 100, 69-72.	2.7	24
818	Inhibitory role of endothelium-derived relaxing factor in rat and human pulmonary arteries. British Journal of Pharmacology, 1990, 101, 166-170.	2.7	53
819	Bradykinin-induced plasma exudation in guinea pig airways: involvement of platelet activating factor. British Journal of Pharmacology, 1990, 101, 739-745.	2.7	52
820	Effect of formoterol, a long-acting beta ₂ -adrenoceptor agonist, against methacholine-induced bronchoconstriction. British Journal of Clinical Pharmacology, 1990, 29, 321-324.	1.1	14
821	Neural control of airway function: New perspectives. Molecular Aspects of Medicine, 1990, 11, 351-423.	2.7	20
822	Neuropeptides as Modulators of Airway Function. , 1990, 31, 175-196.		7
823	Allergic Inflammatory Mediators and Bronchial Hyperresponsiveness. Immunology and Allergy Clinics of North America, 1990, 10, 241-249.	0.7	3
824	Effect of Antiasthma Drugs on Microvascular Leakage in Guinea Pig Airways. The American Review of Respiratory Disease, 1989, 139, 416-421.	2.9	87
825	The Role of Pirenzepine-sensitive (M ₁) Muscarinic Receptors in Vagally Mediated Bronchoconstriction in Humans. The American Review of Respiratory Disease, 1989, 139, 446-449.	2.9	108
826	Anticholinergic Blockade of Beta-Blocker-induced Bronchoconstriction. The American Review of Respiratory Disease, 1989, 139, 1390-1394.	2.9	93
827	Effect of Theophylline and Adenosine on Eosinophil Function. The American Review of Respiratory Disease, 1989, 140, 327-333.	2.9	71
828	A New Approach to the Treatment of Asthma. New England Journal of Medicine, 1989, 321, 1517-1527.	13.9	435

#	ARTICLE	IF	CITATIONS
829	Our changing understanding of asthma. <i>Respiratory Medicine</i> , 1989, 83, 17-23.	1.3	24
830	New concepts in the pathogenesis of bronchial hyperresponsiveness and asthma. <i>Journal of Allergy and Clinical Immunology</i> , 1989, 83, 1013-1026.	1.5	463
831	Evidence for two platelet activating factor receptors on eosinophils: Dissociation between PAF-induced intracellular calcium mobilization degranulation and superoxides anion generation in eosinophils. <i>Biochemical and Biophysical Research Communications</i> , 1989, 162, 511-521.	1.0	75
832	Effects of tachykinins on mucus secretion in human bronchi in vitro. <i>European Journal of Pharmacology</i> , 1989, 174, 283-286.	1.7	114
833	Characterization of platelet-activating factor-induced elevation of cytosolic free calcium concentration in eosinophils. <i>FEBS Letters</i> , 1989, 243, 41-46.	1.3	42
834	Bradykinin-induced bronchoconstriction: inhibition by nedocromil sodium and sodium cromoglycate.. <i>British Journal of Clinical Pharmacology</i> , 1989, 27, 831-836.	1.1	78
835	Effect of infused adenosine on cardiac output and systemic resistance in normal subjects.. <i>British Journal of Clinical Pharmacology</i> , 1989, 27, 165-171.	1.1	39
836	Histamine H ₃ receptors inhibit cholinergic neurotransmission in guinea pig airways. <i>British Journal of Pharmacology</i> , 1989, 97, 13-15.	2.7	108
837	Facilitation by tachykinins of neurotransmission in guinea pig pulmonary parasympathetic nerves. <i>British Journal of Pharmacology</i> , 1989, 97, 274-280.	2.7	74
838	Cholecystokinin octapeptide constricts guinea pig and human airways. <i>British Journal of Pharmacology</i> , 1989, 97, 675-682.	2.7	23
839	Modulation of non-adrenergic, non-cholinergic neural bronchoconstriction in guinea pig airways via GABA _B receptors. <i>British Journal of Pharmacology</i> , 1989, 97, 1225-1231.	2.7	74
840	Purinoceptors in the pulmonary circulation of the rat and their role in hypoxic vasoconstriction. <i>British Journal of Pharmacology</i> , 1989, 98, 367-372.	2.7	23
841	Evidence for two P ₂ purinoceptor subtypes in human small pulmonary arteries. <i>British Journal of Pharmacology</i> , 1989, 98, 1014-1020.	2.7	43
842	Effect of hydrogen peroxide on guinea pig tracheal smooth muscle <i>in vitro</i> : role of cyclooxygenase and airway epithelium. <i>British Journal of Pharmacology</i> , 1989, 98, 325-330.	2.7	84
843	Effects of Nedocromil Sodium on Airway Microvascular Leakage and Neural Reflexes. <i>Drugs</i> , 1989, 37, 94-100.	4.9	5
844	Functional Characteristics of Beta-Adrenergic Receptors of the Intact Eosinophil. <i>Clinical Science</i> , 1989, 76, 14P-14P.	0.0	1
845	Platelet Activating Factor (PAF) Stimulates Phosphoinositide (PI) Metabolism in Guinea Pig Eosinophils. <i>Clinical Science</i> , 1989, 76, 45P-45P.	0.0	2
846	Effect of nedocromil sodium on down-regulation of pulmonary β^2 -adrenoceptors. <i>Clinical Science</i> , 1989, 76, 599-602.	1.8	8

#	ARTICLE	IF	CITATIONS
847	Dilator Action of Ligustrazine on Human and Rat Pulmonary Arteries. <i>Clinical Science</i> , 1989, 77, 27P-27P.	0.0	2
848	Why a new journal?. <i>Pulmonary Pharmacology</i> , 1988, 1, 1.	0.5	0
849	Inflammatory mechanisms and nocturnal asthma. <i>American Journal of Medicine</i> , 1988, 85, 64-70.	0.6	35
850	Radioligand binding of antagonists of platelet-activating factor to intact human platelets. <i>FEBS Letters</i> , 1988, 228, 285-289.	1.3	61
851	Autoradiographic localization of leukotriene C4 and D4 binding sites in guinea-pig lung. <i>Prostaglandins</i> , 1988, 35, 503-513.	1.2	13
852	Effect of inhaled platelet-activating factor on circulating neutrophils and platelets in vivo and ex vivo in man. <i>Prostaglandins</i> , 1988, 36, 343-354.	1.2	9
853	Autoradiographic localization of calcitonin gene-related peptide (CGRP) binding sites in human and guinea pig lung. <i>Peptides</i> , 1988, 9, 957-963.	1.2	87
854	PAF Antagonists. <i>Drugs</i> , 1988, 35, 93-103.	4.9	42
855	Neuropeptides and airway smooth muscle. , 1988, 36, 119-129.		21
856	Comparison of neurokinin A and substance P on cardiovascular and airway function in man.. <i>British Journal of Clinical Pharmacology</i> , 1988, 25, 273-275.	1.1	65
857	Effect of a PAF antagonist, BN52063, on PAF-induced bronchoconstriction in normal subjects.. <i>British Journal of Clinical Pharmacology</i> , 1988, 26, 65-72.	1.1	38
858	Modulation of cholinergic neurotransmission in guinea-pig trachea by neuropeptide Y. <i>British Journal of Pharmacology</i> , 1988, 93, 672-678.	2.7	61
859	Effect of a Paf antagonist, WEB 2086, on airway microvascular leakage in the guinea-pig and platelet aggregation in man. <i>British Journal of Pharmacology</i> , 1988, 94, 164-168.	2.7	40
860	Opioid modulation of non-cholinergic neural bronchoconstriction in guinea-pig <i>in vivo</i> . <i>British Journal of Pharmacology</i> , 1988, 95, 413-418.	2.7	93
861	Effects and interactions of sensory neuropeptides on airway microvascular leakage in guinea-pigs. <i>British Journal of Pharmacology</i> , 1988, 95, 1109-1116.	2.7	120
862	SEVERE PREMENSTRUAL EXACERBATIONS OF ASTHMA: EFFECT OF INTRAMUSCULAR PROGESTERONE. <i>Lancet</i> , The, 1988, 332, 370-372.	6.3	131
863	The Effect of Platelet-activating Factor on Histamine and Muscarinic Receptor Function in Guinea Pig Airways. <i>The American Review of Respiratory Disease</i> , 1988, 137, 1317-1322.	2.9	43
864	Increased Eosinophil Responsiveness to Platelet-Activating Factor in Asthma. <i>Clinical Science</i> , 1988, 74, 5P-5P.	0.0	7

#	ARTICLE	IF	CITATIONS
865	Bradykinin-Induced Microvascular Leakage in Guinea Pig Airways: Involvement of Platelet Activating Factor and Prostanoids. <i>Clinical Science</i> , 1988, 74, 29P-29P.	0.0	1
866	Evidence for Platelet-Activating Factor as a Mediator of Hypoxic Pulmonary Vasoconstriction. <i>Clinical Science</i> , 1988, 75, 21P-21P.	0.0	1
867	Autonomic Control of Airway Function in Asthma. <i>Chest</i> , 1987, 91, 45S-48S.	0.4	5
868	Neuropeptides in Human Airways: Function and Clinical Implications. <i>The American Review of Respiratory Disease</i> , 1987, 136, S77-S83.	2.9	84
869	Cholinergic Control of Airway Smooth Muscle. <i>The American Review of Respiratory Disease</i> , 1987, 136, S42-S45.	2.9	65
870	Epithelial Mediators. <i>The American Review of Respiratory Disease</i> , 1987, 136, S32-S35.	2.9	56
871	Phosphoinositide Turnover. <i>The American Review of Respiratory Disease</i> , 1987, 136, S17-S20.	2.9	27
872	Effects of Infused Adenosine on the Cardiovascular Responses to Orthostasis in Man. <i>Clinical Science</i> , 1987, 72, 9P-9P.	0.0	1
873	Comparison of the Cardiovascular and Respiratory Effects of Substance P and Neurokinin A in Man. <i>Clinical Science</i> , 1987, 72, 41P-41P.	0.0	3
874	Effect of A Platelet Activating Factor (PAF) Antagonist (Web 2086) on Paf Induced Airway Microvascular Leakage and Platelet Aggregation. <i>Clinical Science</i> , 1987, 72, 68P-68P.	0.0	1
875	Airway neuropeptides and asthma. <i>Trends in Pharmacological Sciences</i> , 1987, 8, 24-27.	4.0	83
876	PAF closely mimics pathology of asthma. <i>Trends in Pharmacological Sciences</i> , 1987, 8, 285-287.	4.0	37
877	μ -opioid receptors modulate non-cholinergic constrictor nerves in guinea-pig airways. <i>European Journal of Pharmacology</i> , 1987, 141, 519-522.	1.7	80
878	The effect of platelet activating factor on pulmonary β_2 -adrenoceptors. <i>British Journal of Pharmacology</i> , 1987, 90, 709-715.	2.7	59
879	Sensory neuropeptide effects in human skin. <i>British Journal of Pharmacology</i> , 1987, 92, 781-788.	2.7	91
880	Calcitonin gene-related peptide (CGRP) is a potent non-endothelium-dependent inhibitor of coronary vasomotor tone. <i>British Journal of Pharmacology</i> , 1987, 92, 789-794.	2.7	82
881	The effect of an angiotensin converting enzyme inhibitor, ramipril, on bronchial responses to inhaled histamine and bradykinin in asthmatic subjects.. <i>British Journal of Clinical Pharmacology</i> , 1987, 23, 91-93.	1.1	40
882	Circulatory and respiratory effects of infused adenosine in conscious man.. <i>British Journal of Clinical Pharmacology</i> , 1987, 24, 306-317.	1.1	63

#	ARTICLE	IF	CITATIONS
883	EFFECT OF A GINKGOLIDE MIXTURE (BN 52063) IN ANTAGONISING SKIN AND PLATELET RESPONSES TO PLATELET ACTIVATING FACTOR IN MAN. <i>Lancet, The</i> , 1987, 329, 248-251.	6.3	251
884	New Concepts in the Pathogenesis of Bronchial Hyperresponsiveness. , 1987, 21, 225-237.		4
885	Autoradiographic mapping of substance p receptors in lung. <i>European Journal of Pharmacology</i> , 1986, 127, 295-296.	1.7	123
886	Vasoactive intestinal peptide in bovine pulmonary artery: localisation, function and receptor autoradiography. <i>British Journal of Pharmacology</i> , 1986, 89, 157-162.	2.7	46
887	Histamine is released from skin by substance P but does not act as the final vasodilator in the axon reflex. <i>British Journal of Pharmacology</i> , 1986, 88, 741-745.	2.7	116
888	THE CHRONOPHARMACOLOGY AND CHRONOTHERAPY OF ASTHMA. , 1986, , 229-273.		32
889	A Comparison of the Cutaneous Actions of Substance P and Calcitonin Gene Related Peptide in Man. <i>Clinical Science</i> , 1986, 70, 54P-54P.	0.0	0
890	Platelet Activating Factor Increases Vascular Permeability in Guinea Pig Airways. <i>Clinical Science</i> , 1986, 71, 1P-1P.	0.0	4
891	Influence of Autonomic Blockade on Cardiovascular effects of Infused Adenosine in Man. <i>Clinical Science</i> , 1986, 71, 45P-45P.	0.0	1
892	Reduction of Nocturnal Asthma by an Inhaled Anticholinergic Drug. <i>Chest</i> , 1986, 90, 485-488.	0.4	81
893	Calcium, Calcium Channel Blockade and Airways Function. <i>Acta Pharmacologica Et Toxicologica</i> , 1986, 58, 91-111.	0.0	13
894	The Effect of Posture on Slow Release Theophylline Pharmacokinetics. <i>Clinical Science</i> , 1985, 68, 4P-5P.	0.0	1
895	Inhaled Nifedipine Reverses Histamine-Induced Bronchoconstriction in Man. <i>Clinical Science</i> , 1985, 68, 5P-5P.	0.0	1
896	Histamine, Substance P and Neurogenic Flare in Human Skin. <i>Clinical Science</i> , 1985, 68, 23P-24P.	0.0	3
897	Distribution of Beta-Adrenoceptor Subtypes in Human Lung. <i>Clinical Science</i> , 1985, 68, 35P-35P.	0.0	0
898	The Effect of Vasoactive Intestinal Peptide on Human Airway Smooth Muscle in-vitro. <i>Clinical Science</i> , 1985, 68, 58P-58P.	0.0	1
899	The Influence of Epithelium on Airway Smooth Muscle Contraction. <i>Clinical Science</i> , 1985, 68, 59P-59P.	0.0	1
900	Substance P Enhances the Transient Ventilatory Hypoxic Response in Man. <i>Clinical Science</i> , 1985, 69, 59P-59P.	0.0	0

#	ARTICLE	IF	CITATIONS
901	The effect of airway epithelium on smooth muscle contractility in bovine trachea. British Journal of Pharmacology, 1985, 86, 685-691.	2.7	258
902	Posture and theophylline kinetics.. British Journal of Clinical Pharmacology, 1985, 19, 707-709.	1.1	43
903	Circadian variation in airway function. American Journal of Medicine, 1985, 79, 5-9.	0.6	77
904	The Effect of Inhaled Vasoactive Intestinal Peptide on Bronchial Reactivity to Histamine in Humans. The American Review of Respiratory Disease, 1984, 130, 162-166.	2.9	111
905	Plasma Catecholamine Concentrations in Acute Severe Asthma and Antigen-Induced Bronchoconstriction. Clinical Science, 1984, 67, 34P-35P.	0.0	1
906	Hypoxia and Catecholamine Secretion in Normal Man. Clinical Science, 1984, 67, 58P-59P.	0.0	0
907	Regional Ventilation Perfusion Ratio and Specific Ventilation in Asthmatics Using Positron Emission Tomography (PET). Clinical Science, 1984, 67, 59P-60P.	0.0	0
908	Nifedipine Prolongs Isoprenaline-Induced Bronchodilatation in Normal Subjects. Clinical Science, 1984, 67, 62P-62P.	0.0	1
909	SINGLE-DOSE SLOW-RELEASE AMINOPHYLLINE AT NIGHT PREVENTS NOCTURNAL ASTHMA. Lancet, The, 1982, 319, 299-301.	6.3	148
910	Localization of β_2 -adrenoreceptors in mammalian lung by light microscopic autoradiography. Nature, 1982, 299, 444-447.	13.7	131
911	CIRCULATING CATECHOLAMINES IN ASTHMA. Clinical Physiology, 1981, 1, 89-93.	0.7	6
912	Role of Endogenous Opiates in Control of Breathing. Clinical Science, 1981, 61, 4P-5P.	1.8	1
913	Increased pulmonary β_1 -adrenergic and reduced β_2 -adrenergic receptors in experimental asthma. Nature, 1980, 285, 569-571.	13.7	186
914	Nocturnal Asthma and Changes in Circulating Epinephrine, Histamine, and Cortisol. New England Journal of Medicine, 1980, 303, 263-267.	13.9	423